

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus nr 1: *Kas kõigil prediabeediga inimestel kasutada elustiili sekkumist või farmakoloogilist ravi suukaudse diabeedi ravimiga või mõlemat või mitte midagi, 2. tüüpi diabeedi ennetamiseks?*

Kuupäev (pp.kk.aasta)	01.08.2020 (1)
Otsingu läbiviija	Anna Vesper
Andmebaas	Pubmed
Otsistrateegia (päring)	<p>((intermediate hyperglycaemi*[Title/Abstract] OR intermediate hyperglycemi*[Title/Abstract] OR pre-diabet*[Title/Abstract] OR prediabet*[Title/Abstract] OR pre diabet*[Title/Abstract] OR IGT[Title/Abstract] OR IFG[Title/Abstract] OR prediabetic state*[Title/Abstract] OR impaired glucose metabolism[Title/Abstract] OR impaired glucose tolerance[Title/Abstract] OR impaired FPG[Title/Abstract] OR impaired fasting glucose[Title/Abstract] OR glucose intolerance[Title/Abstract] OR "Glucose Intolerance"[Mesh] OR "Prediabetic State"[Mesh]) AND (aged[Title/Abstract] OR adult*[Title/Abstract] OR "Adult"[Mesh])) AND (jardiance*[Title/Abstract] OR BI-10773[Title/Abstract] OR BI 10773[Title/Abstract] OR BI10773[Title/Abstract] OR empagliflozin*[Title/Abstract] OR forxiga*[Title/Abstract] OR BMS-512148[Title/Abstract] OR BMS 512148[Title/Abstract] OR BMS512148[Title/Abstract] OR dapagliflozin*[Title/Abstract] OR invokana*[Title/Abstract] OR canagliflozin*[Title/Abstract] OR "Canagliflozin"[Mesh] OR SGLT-2 inhibitor*[Title/Abstract] OR SGLT 2 inhibitor*[Title/Abstract] OR SGLT2 inhibitor*[Title/Abstract] OR gliflozin*[Title/Abstract] OR sodium glucose cotransporter 2 inhibitor*[Title/Abstract] OR sodium glucose co transporter 2 inhibitor*[Title/Abstract] OR sodium glucose co-transporter 2 inhibitor*[Title/Abstract] OR sodium glucose transporter 2 inhibitor*[Title/Abstract] OR "Sodium-Glucose Transporter 2 Inhibitors"[Mesh] OR oltar*[Title/Abstract] OR amarel*[Title/Abstract] OR amaryl*[Title/Abstract] OR HOE-490[Title/Abstract] OR HOE 490[Title/Abstract] OR HOE490[Title/Abstract] OR glymepiride*[Title/Abstract] OR glimepiride*[Title/Abstract] OR glibenese*[Title/Abstract] OR glupitel*[Title/Abstract] OR ozidia*[Title/Abstract] OR melizide*[Title/Abstract] OR mindiab*[Title/Abstract] OR minidiab*[Title/Abstract] OR glucotrol*[Title/Abstract] OR glydiazinamide*[Title/Abstract] OR glidiazinamid*[Title/Abstract] OR glypidizine*[Title/Abstract] OR minodiab*[Title/Abstract] OR K-4024[Title/Abstract] OR K 4024[Title/Abstract] OR K4024[Title/Abstract] OR glipizide*[Title/Abstract] OR</p>

	<p>"Glipizide"[Mesh] OR diaprel*[Title/Abstract] OR diabrezide*[Title/Abstract] OR diamicon*[Title/Abstract] OR glyade*[Title/Abstract] OR glyclazide*[Title/Abstract] OR S-1702[Title/Abstract] OR S 1702[Title/Abstract] OR S1702[Title/Abstract] OR S-852[Title/Abstract] OR S 852[Title/Abstract] OR S852[Title/Abstract] OR gliclazide*[Title/Abstract] OR "Gliclazide"[Mesh] OR sulphonylurea*[Title/Abstract] OR sulfonylureas*[Title/Abstract] OR "Sulfonylurea Compounds"[Mesh:NoExp] OR AD 4833[Title/Abstract] OR AD-4833[Title/Abstract] OR AD4833[Title/Abstract] OR actos*[Title/Abstract] OR pioglitazone*[Title/Abstract] OR TZD*[Title/Abstract] OR glitazone*[Title/Abstract] OR thiazolidinedione*[Title/Abstract] OR "Pioglitazone"[Mesh] OR "Thiazolidinediones"[Mesh:NoExp] OR vipidia*[Title/Abstract] OR nesina*[Title/Abstract] OR SYR-322[Title/Abstract] OR SYR322[Title/Abstract] OR SYR 322[Title/Abstract] OR alogliptin*[Title/Abstract] OR galvus*[Title/Abstract] OR LAF-237[Title/Abstract] OR LAF237[Title/Abstract] OR LAF 237[Title/Abstract] OR vildagliptin[Title/Abstract] OR "Vildagliptin"[Mesh] OR tradjenta*[Title/Abstract] OR trajenta*[Title/Abstract] OR BI-1356[Title/Abstract] OR BI 1356[Title/Abstract] OR BI1356[Title/Abstract] OR linagliptin*[Title/Abstract] OR "Linagliptin"[Mesh] OR onglyza*[Title/Abstract] OR BMS-477118[Title/Abstract] OR BMS477118[Title/Abstract] OR BMS 477118[Title/Abstract] OR saxagliptin*[Title/Abstract] OR januvia*[Title/Abstract] OR MK-0431[Title/Abstract] OR MK0431[Title/Abstract] OR MK 0431[Title/Abstract] OR sitagliptin*[Title/Abstract] OR "Sitagliptin Phosphate"[Mesh:NoExp] OR gliptin*[Title/Abstract] OR dpp IV inhibitor*[Title/Abstract] OR dpp 4 inhibitor*[Title/Abstract] OR dipeptidylpeptidase IV inhibitor*[Title/Abstract] OR dipeptidylpeptidase 4 inhibitor*[Title/Abstract] OR dipeptidyl peptidase IV inhibitor*[Title/Abstract] OR dipeptidyl peptidase 4 inhibitor*[Title/Abstract] OR "Dipeptidyl-Peptidase IV Inhibitors"[Mesh] OR metformin*[Title/Abstract] OR "Metformin"[Mesh:NoExp])) AND (Randomized Controlled Trial[PT] OR Randomized Controlled Trials[MeSH] OR randomized controlled trial*[tiab] OR randomized control trial*[tiab] OR (Clinical Trial[PT] AND (Random Allocation[MeSH] OR random*[tiab] OR Double-blind Method[MeSH] OR double blind*[tiab])))</p>
Tulemuste arv	87
Andmebaasi filtrid	English, Finnish
Ajaline piirang (ilmumisaeg)	01.01.2015-01.08.2020

Muud piirangud	Ei rakendatud
----------------	---------------

Kuupäev (pp.kk.aasta)	01.08.2020 (2)
Otsingu läbiviija	Anna Vesper
Andmebaas	Pubmed
Otsistrateegia (päring)	(((intermediate hyperglycaemi*[Title/Abstract] OR intermediate hyperglycemi*[Title/Abstract] OR pre-diabet*[Title/Abstract] OR prediabet*[Title/Abstract] OR pre diabet*[Title/Abstract] OR IGT[Title/Abstract] OR IFG[Title/Abstract] OR prediabetic state*[Title/Abstract] OR impaired glucose metabolism[Title/Abstract] OR impaired glucose tolerance[Title/Abstract] OR impaired FPG[Title/Abstract] OR impaired fasting glucose[Title/Abstract] OR glucose intolerance[Title/Abstract] OR "Glucose Intolerance"[Mesh] OR "Prediabetic State"[Mesh]) AND (aged[Title/Abstract] OR adult*[Title/Abstract] OR "Adult"[Mesh])) AND (jardiance*[Title/Abstract] OR BI-10773[Title/Abstract] OR BI 10773[Title/Abstract] OR BI10773[Title/Abstract] OR empagliflozin*[Title/Abstract] OR forxiga*[Title/Abstract] OR BMS-512148[Title/Abstract] OR BMS 512148[Title/Abstract] OR BMS512148[Title/Abstract] OR dapagliflozin*[Title/Abstract] OR invokana*[Title/Abstract] OR canagliflozin*[Title/Abstract] OR "Canagliflozin"[Mesh] OR SGLT-2 inhibitor*[Title/Abstract] OR SGLT 2 inhibitor*[Title/Abstract] OR SGLT2 inhibitor*[Title/Abstract] OR gliflozin*[Title/Abstract] OR sodium glucose cotransporter 2 inhibitor*[Title/Abstract] OR sodium glucose co transporter 2 inhibitor*[Title/Abstract] OR sodium glucose co-transporter 2 inhibitor*[Title/Abstract] OR sodium glucose transporter 2 inhibitor*[Title/Abstract] OR "Sodium-Glucose Transporter 2 Inhibitors"[Mesh] OR oltar*[Title/Abstract] OR amarel*[Title/Abstract] OR amaryl*[Title/Abstract] OR HOE-490[Title/Abstract] OR HOE 490[Title/Abstract] OR HOE490[Title/Abstract] OR glymepiride*[Title/Abstract] OR glimepiride*[Title/Abstract] OR glibenese*[Title/Abstract] OR glupitel*[Title/Abstract] OR ozidia*[Title/Abstract] OR melizide*[Title/Abstract] OR mindiab*[Title/Abstract] OR minidiab*[Title/Abstract] OR glucotrol*[Title/Abstract] OR glydiazinamide*[Title/Abstract] OR glidiazinamid*[Title/Abstract] OR glypidizine*[Title/Abstract] OR minodiab*[Title/Abstract] OR K-4024[Title/Abstract] OR K 4024[Title/Abstract] OR K4024[Title/Abstract] OR glipizide*[Title/Abstract] OR "Glipizide"[Mesh] OR diaprel*[Title/Abstract] OR diabrezide*[Title/Abstract] OR diamicon*[Title/Abstract] OR glyade*[Title/Abstract] OR glyclazide*[Title/Abstract] OR S-

	<p>1702[Title/Abstract] OR S 1702[Title/Abstract] OR S1702[Title/Abstract] OR S-852[Title/Abstract] OR S 852[Title/Abstract] OR S852[Title/Abstract] OR gliclazide*[Title/Abstract] OR "Gliclazide"[Mesh] OR sulphonylurea*[Title/Abstract] OR sulfonylureas*[Title/Abstract] OR "Sulfonylurea Compounds"[Mesh:NoExp] OR AD 4833[Title/Abstract] OR AD-4833[Title/Abstract] OR AD4833[Title/Abstract] OR actos*[Title/Abstract] OR pioglitazone*[Title/Abstract] OR TZD[Title/Abstract] OR glitazone*[Title/Abstract] OR thiazolidinedione*[Title/Abstract] OR "Pioglitazone"[Mesh] OR "Thiazolidinediones"[Mesh:NoExp] OR vipidia*[Title/Abstract] OR nesina*[Title/Abstract] OR SYR-322[Title/Abstract] OR SYR322[Title/Abstract] OR SYR 322[Title/Abstract] OR alogliptin*[Title/Abstract] OR galvus*[Title/Abstract] OR LAF-237[Title/Abstract] OR LAF237[Title/Abstract] OR LAF 237[Title/Abstract] OR vildagliptin[Title/Abstract] OR "Vildagliptin"[Mesh] OR tradjenta*[Title/Abstract] OR trajenta*[Title/Abstract] OR BI-1356[Title/Abstract] OR BI 1356[Title/Abstract] OR BI1356[Title/Abstract] OR linagliptin*[Title/Abstract] OR "Linagliptin"[Mesh] OR onglyza*[Title/Abstract] OR BMS-477118[Title/Abstract] OR BMS477118[Title/Abstract] OR BMS 477118[Title/Abstract] OR saxagliptin*[Title/Abstract] OR januvia*[Title/Abstract] OR MK-0431[Title/Abstract] OR MK0431[Title/Abstract] OR MK 0431[Title/Abstract] OR sitagliptin*[Title/Abstract] OR "Sitagliptin Phosphate"[Mesh:NoExp] OR gliptin*[Title/Abstract] OR dpp IV inhibitor*[Title/Abstract] OR dpp 4 inhibitor*[Title/Abstract] OR dipeptidylpeptidase IV inhibitor*[Title/Abstract] OR dipeptidylpeptidase 4 inhibitor*[Title/Abstract] OR dipeptidyl peptidase IV inhibitor*[Title/Abstract] OR dipeptidyl peptidase 4 inhibitor*[Title/Abstract] OR "Dipeptidyl-Peptidase IV Inhibitors"[Mesh] OR metformin*[Title/Abstract] OR "Metformin"[Mesh:NoExp])) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])</p>
Tulemuste arv	14
Andmebaasi filtrid	English, Finnish
Ajaline piirang (ilmumisaeg)	Ei rakendatud
Muud piirangud	Ei rakendatud

Kuupäev (pp.kk.aasta)	01.08.2020 (3)
Otsingu läbiviija	Anna Vesper
Andmebaas	Pubmed
Otsistrateegia (päring)	((intermediate hyperglycaemi*[Title/Abstract] OR intermediate hyperglycemi*[Title/Abstract] OR pre-diabet*[Title/Abstract] OR prediabet*[Title/Abstract] OR pre diabet*[Title/Abstract] OR IGT[Title/Abstract] OR IFG[Title/Abstract] OR prediabetic state*[Title/Abstract] OR impaired glucose metabolism[Title/Abstract] OR impaired glucose tolerance[Title/Abstract] OR impaired FPG[Title/Abstract] OR impaired fasting glucose[Title/Abstract] OR glucose intolerance[Title/Abstract] OR "Glucose Intolerance"[Mesh] OR "Prediabetic State"[Mesh]) AND (aged[Title/Abstract] OR adult*[Title/Abstract] OR "Adult"[Mesh])) AND (nutrition program*[Title/Abstract] OR nutrition modif*[Title/Abstract] OR nutrition change*[Title/Abstract] OR nutrition intervention*[Title/Abstract] OR dietary modification*[Title/Abstract] OR diet modification*[Title/Abstract] OR diet*[Title/Abstract] OR life style program*[Title/Abstract] OR life style modif*[Title/Abstract] OR life style change*[Title/Abstract] OR life style intervention*[Title/Abstract] OR lifestyle program*[Title/Abstract] OR lifestyle modif*[Title/Abstract] OR lifestyle change*[Title/Abstract] OR lifestyle intervention*[Title/Abstract] OR "Exercise Therapy"[Mesh] OR "Exercise"[Mesh] OR "Diet Therapy"[Mesh] OR "Diet"[Mesh] OR "Healthy Lifestyle"[Mesh:NoExp] OR "Life Style"[Mesh:NoExp])) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])
Tulemuste arv	93
Andmebaasi filtrid	English, Finnish
Ajaline piirang (ilmumisaeg)	Ei rakendatud
Muud piirangud	Ei rakendatud
Märkused	Otsing 48 (veel üks maha, CR vana)

Kuupäev (pp.kk.aasta)	02.08.2020 (4)
Otsingu läbiviija	Anna Vesper
Andmebaas	Pubmed
Otsistrateegia (päring)	((intermediate hyperglycaemi*[Title/Abstract] OR intermediate hyperglycemi*[Title/Abstract] OR pre-diabet*[Title/Abstract] OR prediabet*[Title/Abstract] OR pre diabet*[Title/Abstract] OR

	IGT[Title/Abstract] OR IFG[Title/Abstract] OR prediabetic state*[Title/Abstract] OR impaired glucose metabolism[Title/Abstract] OR impaired glucose tolerance[Title/Abstract] OR impaired FPG[Title/Abstract] OR impaired fasting glucose[Title/Abstract] OR glucose intolerance[Title/Abstract] OR "Glucose Intolerance"[Mesh] OR "Prediabetic State"[Mesh]) AND (aged[Title/Abstract] OR adult*[Title/Abstract] OR "Adult"[Mesh])) AND (nutrition program*[Title/Abstract] OR nutrition modif*[Title/Abstract] OR nutrition change*[Title/Abstract] OR nutrition intervention*[Title/Abstract] OR dietary modification*[Title/Abstract] OR diet modification*[Title/Abstract] OR diet*[Title/Abstract] OR life style program*[Title/Abstract] OR life style modif*[Title/Abstract] OR life style change*[Title/Abstract] OR life style intervention*[Title/Abstract] OR lifestyle program*[Title/Abstract] OR lifestyle modif*[Title/Abstract] OR lifestyle change*[Title/Abstract] OR lifestyle intervention*[Title/Abstract] OR "Exercise Therapy"[Mesh] OR "Exercise"[Mesh] OR "Diet Therapy"[Mesh] OR "Diet"[Mesh] OR "Healthy Lifestyle"[Mesh:NoExp] OR "Life Style"[Mesh:NoExp])) AND (Randomized Controlled Trial[PT] OR Randomized Controlled Trials[MeSH] OR randomized controlled trial*[tiab] OR randomized control trial*[tiab] OR (Clinical Trial[PT] AND (Random Allocation[MeSH] OR random*[tiab] OR Double-blind Method[MeSH] OR double blind*[tiab])))
Tulemuste arv	402
Andmebaasi filtrid	English, Finnish
Ajaline piirang (ilmumisaeg)	01.01.2015-02.08.2020
Muud piirangud	Ei rakendatud

Kuupäev (pp.kk.aasta)	02.08.2020 (5)
Otsingu läbiviija	Anna Vesper
Andmebaas	Pubmed
Otsistrateegia (päring)	((intermediate hyperglycaemi*[Title/Abstract] OR intermediate hyperglycemi*[Title/Abstract] OR pre-diabet*[Title/Abstract] OR prediabet*[Title/Abstract] OR pre diabet*[Title/Abstract] OR IGT[Title/Abstract] OR IFG[Title/Abstract] OR prediabetic state*[Title/Abstract] OR impaired glucose metabolism[Title/Abstract] OR impaired glucose tolerance[Title/Abstract] OR impaired FPG[Title/Abstract] OR impaired fasting glucose[Title/Abstract] OR glucose intolerance[Title/Abstract] OR "Glucose Intolerance"[Mesh] OR

"Prediabetic State"[Mesh]) AND (aged[Title/Abstract] OR adult*[Title/Abstract] OR "Adult"[Mesh])) AND ((nutrition program*[Title/Abstract] OR nutrition modif*[Title/Abstract] OR nutrition change*[Title/Abstract] OR nutrition intervention*[Title/Abstract] OR dietary modification*[Title/Abstract] OR diet modification*[Title/Abstract] OR diet*[Title/Abstract] OR life style program*[Title/Abstract] OR life style modif*[Title/Abstract] OR life style change*[Title/Abstract] OR life style intervention*[Title/Abstract] OR lifestyle program*[Title/Abstract] OR lifestyle modif*[Title/Abstract] OR lifestyle change*[Title/Abstract] OR lifestyle intervention*[Title/Abstract] OR "Exercise Therapy"[Mesh] OR "Exercise"[Mesh] OR "Diet Therapy"[Mesh] OR "Diet"[Mesh] OR "Healthy Lifestyle"[Mesh:NoExp] OR "Life Style"[Mesh:NoExp]) AND (jardiance*[Title/Abstract] OR BI-10773[Title/Abstract] OR BI 10773[Title/Abstract] OR BI10773[Title/Abstract] OR empagliflozin*[Title/Abstract] OR forxiga*[Title/Abstract] OR BMS-512148[Title/Abstract] OR BMS 512148[Title/Abstract] OR BMS512148[Title/Abstract] OR dapagliflozin*[Title/Abstract] OR invokana*[Title/Abstract] OR canagliflozin*[Title/Abstract] OR "Canagliflozin"[Mesh] OR SGLT-2 inhibitor*[Title/Abstract] OR SGLT 2 inhibitor*[Title/Abstract] OR SGLT2 inhibitor*[Title/Abstract] OR gliflozin*[Title/Abstract] OR sodium glucose cotransporter 2 inhibitor*[Title/Abstract] OR sodium glucose co transporter 2 inhibitor*[Title/Abstract] OR sodium glucose co-transporter 2 inhibitor*[Title/Abstract] OR sodium glucose transporter 2 inhibitor*[Title/Abstract] OR "Sodium-Glucose Transporter 2 Inhibitors"[Mesh] OR oltar*[Title/Abstract] OR amarel*[Title/Abstract] OR amaryl*[Title/Abstract] OR HOE-490[Title/Abstract] OR HOE 490[Title/Abstract] OR HOE490[Title/Abstract] OR glymepiride*[Title/Abstract] OR glimepiride*[Title/Abstract] OR glibenese*[Title/Abstract] OR glupitel*[Title/Abstract] OR ozidia*[Title/Abstract] OR melizide*[Title/Abstract] OR mindiab*[Title/Abstract] OR minidiab*[Title/Abstract] OR glucotrol*[Title/Abstract] OR glydiazinamide*[Title/Abstract] OR glidiazinamid*[Title/Abstract] OR glypidizine*[Title/Abstract] OR minodiab*[Title/Abstract] OR K-4024[Title/Abstract] OR K 4024[Title/Abstract] OR K4024[Title/Abstract] OR glipizide*[Title/Abstract] OR "Glipizide"[Mesh] OR diaprel*[Title/Abstract] OR diabrezide*[Title/Abstract] OR diamicon*[Title/Abstract] OR glyade*[Title/Abstract] OR glyclazide*[Title/Abstract] OR S-1702[Title/Abstract] OR S 1702[Title/Abstract] OR S1702[Title/Abstract] OR S-852[Title/Abstract] OR S 852[Title/Abstract] OR S852[Title/Abstract] OR

	<p>gliclazide*[Title/Abstract] OR "Gliclazide"[Mesh] OR sulphonylurea*[Title/Abstract] OR sulfonyleureas*[Title/Abstract] OR "Sulfonylurea Compounds"[Mesh:NoExp] OR AD 4833[Title/Abstract] OR AD-4833[Title/Abstract] OR AD4833[Title/Abstract] OR actos*[Title/Abstract] OR pioglitazone*[Title/Abstract] OR TZD*[Title/Abstract] OR glitazone*[Title/Abstract] OR thiazolidinedione*[Title/Abstract] OR "Pioglitazone"[Mesh] OR "Thiazolidinediones"[Mesh:NoExp] OR vipidia*[Title/Abstract] OR nesina*[Title/Abstract] OR SYR-322[Title/Abstract] OR SYR322[Title/Abstract] OR SYR 322[Title/Abstract] OR alogliptin*[Title/Abstract] OR galvus*[Title/Abstract] OR LAF-237[Title/Abstract] OR LAF237[Title/Abstract] OR LAF 237[Title/Abstract] OR vildagliptin[Title/Abstract] OR "Vildagliptin"[Mesh] OR tradjenta*[Title/Abstract] OR trajenta*[Title/Abstract] OR BI-1356[Title/Abstract] OR BI 1356[Title/Abstract] OR BI1356[Title/Abstract] OR linagliptin*[Title/Abstract] OR "Linagliptin"[Mesh] OR onglyza*[Title/Abstract] OR BMS-477118[Title/Abstract] OR BMS477118[Title/Abstract] OR BMS 477118[Title/Abstract] OR saxagliptin*[Title/Abstract] OR januvia*[Title/Abstract] OR MK-0431[Title/Abstract] OR MK0431[Title/Abstract] OR MK 0431[Title/Abstract] OR sitagliptin*[Title/Abstract] OR "Sitagliptin Phosphate"[Mesh:NoExp] OR gliptin*[Title/Abstract] OR dpp IV inhibitor*[Title/Abstract] OR dpp 4 inhibitor*[Title/Abstract] OR dipeptidylpeptidase IV inhibitor*[Title/Abstract] OR dipeptidylpeptidase 4 inhibitor*[Title/Abstract] OR dipeptidyl peptidase IV inhibitor*[Title/Abstract] OR dipeptidyl peptidase 4 inhibitor*[Title/Abstract] OR "Dipeptidyl-Peptidase IV Inhibitors"[Mesh] OR metformin*[Title/Abstract] OR "Metformin"[Mesh:NoExp])) AND (Randomized Controlled Trial[PT] OR Randomized Controlled Trials[MeSH] OR randomized controlled trial*[tiab] OR randomized control trial*[tiab] OR (Clinical Trial[PT] AND (Random Allocation[MeSH] OR random*[tiab] OR Double-blind Method[MeSH] OR double blind*[tiab])))</p>
Tulemuste arv	44
Andmebaasi filtrid	English, Finnish
Ajaline piirang (ilmumisaeg)	01.01.2015-02.08.2020
Muud piirangud	Ei rakendatud
Märkused	Kõik kirjed tulnud välja eelnevate otsingutega

Kuupäev (pp.kk.aasta)	02.08.2020 (6)
Otsingu läbiviija	Anna Vesper

Andmebaas	Pubmed
Otsistrateegia (päring)	<p>(((intermediate hyperglycaemi*[Title/Abstract] OR intermediate hyperglycemi*[Title/Abstract] OR pre-diabet*[Title/Abstract] OR prediabet*[Title/Abstract] OR pre diabet*[Title/Abstract] OR IGT[Title/Abstract] OR IFG[Title/Abstract] OR prediabetic state*[Title/Abstract] OR impaired glucose metabolism[Title/Abstract] OR impaired glucose tolerance[Title/Abstract] OR impaired FPG[Title/Abstract] OR impaired fasting glucose[Title/Abstract] OR glucose intolerance[Title/Abstract] OR "Glucose Intolerance"[Mesh] OR "Prediabetic State"[Mesh]) AND (aged[Title/Abstract] OR adult*[Title/Abstract] OR "Adult"[Mesh])) AND ((nutrition program*[Title/Abstract] OR nutrition modif*[Title/Abstract] OR nutrition change*[Title/Abstract] OR nutrition intervention*[Title/Abstract] OR dietary modification*[Title/Abstract] OR diet modification*[Title/Abstract] OR diet*[Title/Abstract] OR life style program*[Title/Abstract] OR life style modif*[Title/Abstract] OR life style change*[Title/Abstract] OR life style intervention*[Title/Abstract] OR lifestyle program*[Title/Abstract] OR lifestyle modif*[Title/Abstract] OR lifestyle change*[Title/Abstract] OR lifestyle intervention*[Title/Abstract] OR "Exercise Therapy"[Mesh] OR "Exercise"[Mesh] OR "Diet Therapy"[Mesh] OR "Diet"[Mesh] OR "Healthy Lifestyle"[Mesh:NoExp] OR "Life Style"[Mesh:NoExp]) AND (jardiance*[Title/Abstract] OR BI-10773[Title/Abstract] OR BI 10773[Title/Abstract] OR BI10773[Title/Abstract] OR empagliflozin*[Title/Abstract] OR forxiga*[Title/Abstract] OR BMS-512148[Title/Abstract] OR BMS 512148[Title/Abstract] OR BMS512148[Title/Abstract] OR dapagliflozin*[Title/Abstract] OR invokana*[Title/Abstract] OR canagliflozin*[Title/Abstract] OR "Canagliflozin"[Mesh] OR SGLT-2 inhibitor*[Title/Abstract] OR SGLT 2 inhibitor*[Title/Abstract] OR SGLT2 inhibitor*[Title/Abstract] OR gliflozin*[Title/Abstract] OR sodium glucose cotransporter 2 inhibitor*[Title/Abstract] OR sodium glucose co transporter 2 inhibitor*[Title/Abstract] OR sodium glucose co-transporter 2 inhibitor*[Title/Abstract] OR sodium glucose transporter 2 inhibitor*[Title/Abstract] OR "Sodium-Glucose Transporter 2 Inhibitors"[Mesh] OR oltar*[Title/Abstract] OR amarel*[Title/Abstract] OR amaryl*[Title/Abstract] OR HOE-490[Title/Abstract] OR HOE 490[Title/Abstract] OR HOE490[Title/Abstract] OR glymepiride*[Title/Abstract] OR glimepiride*[Title/Abstract] OR glibenese*[Title/Abstract] OR glupitel*[Title/Abstract] OR ozidia*[Title/Abstract] OR melizide*[Title/Abstract] OR mindiab*[Title/Abstract] OR minidiab*[Title/Abstract] OR glucotrol*[Title/Abstract] OR</p>

	<p>glydiazinamide*[Title/Abstract] OR glidiazinamid*[Title/Abstract] OR glypidizine*[Title/Abstract] OR minodiab*[Title/Abstract] OR K-4024[Title/Abstract] OR K 4024[Title/Abstract] OR K4024[Title/Abstract] OR glipizide*[Title/Abstract] OR "Glipizide"[Mesh] OR diaprel*[Title/Abstract] OR diabrezide*[Title/Abstract] OR diamicon*[Title/Abstract] OR glyade*[Title/Abstract] OR glyclazide*[Title/Abstract] OR S-1702[Title/Abstract] OR S 1702[Title/Abstract] OR S1702[Title/Abstract] OR S-852[Title/Abstract] OR S 852[Title/Abstract] OR S852[Title/Abstract] OR gliclazide*[Title/Abstract] OR "Gliclazide"[Mesh] OR sulphonylurea*[Title/Abstract] OR sulfonylureas*[Title/Abstract] OR "Sulfonylurea Compounds"[Mesh:NoExp] OR AD 4833[Title/Abstract] OR AD-4833[Title/Abstract] OR AD4833[Title/Abstract] OR actos*[Title/Abstract] OR pioglitazone*[Title/Abstract] OR TZD[Title/Abstract] OR glitazone*[Title/Abstract] OR thiazolidinedione*[Title/Abstract] OR "Pioglitazone"[Mesh] OR "Thiazolidinediones"[Mesh:NoExp] OR vipidia*[Title/Abstract] OR nesina*[Title/Abstract] OR SYR-322[Title/Abstract] OR SYR322[Title/Abstract] OR SYR 322[Title/Abstract] OR alogliptin*[Title/Abstract] OR galvus*[Title/Abstract] OR LAF-237[Title/Abstract] OR LAF237[Title/Abstract] OR LAF 237[Title/Abstract] OR vildagliptin[Title/Abstract] OR "Vildagliptin"[Mesh] OR tradjenta*[Title/Abstract] OR trajenta*[Title/Abstract] OR BI-1356[Title/Abstract] OR BI 1356[Title/Abstract] OR BI1356[Title/Abstract] OR linagliptin*[Title/Abstract] OR "Linagliptin"[Mesh] OR onglyza*[Title/Abstract] OR BMS-477118[Title/Abstract] OR BMS477118[Title/Abstract] OR BMS 477118[Title/Abstract] OR saxagliptin*[Title/Abstract] OR januvia*[Title/Abstract] OR MK-0431[Title/Abstract] OR MK0431[Title/Abstract] OR MK 0431[Title/Abstract] OR sitagliptin*[Title/Abstract] OR "Sitagliptin Phosphate"[Mesh:NoExp] OR gliptin*[Title/Abstract] OR dpp IV inhibitor*[Title/Abstract] OR dpp 4 inhibitor*[Title/Abstract] OR dipeptidylpeptidase IV inhibitor*[Title/Abstract] OR dipeptidylpeptidase 4 inhibitor*[Title/Abstract] OR dipeptidyl peptidase IV inhibitor*[Title/Abstract] OR dipeptidyl peptidase 4 inhibitor*[Title/Abstract] OR "Dipeptidyl-Peptidase IV Inhibitors"[Mesh] OR metformin*[Title/Abstract] OR "Metformin"[Mesh:NoExp])) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])</p>
Tulemuste arv	10

Andmebaasi filtrid	English, Finnish
Ajaline piirang (ilmumisaeg)	Ei rakendatud
Muud piirangud	Ei rakendatud
Märkused	Kõik kirjed tulnud välja eelnevate otsingutega.


Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- uuringud, mis käsitlevad prediabeedi korral kasutatavaid sekkumisi (elustiili sekkumised, ravimid)
- süstemaatilised ülevaated, metaanalüüsid, randomiseeritud kontrollitud uuringud
- ingliskeelsed, soomekeelsed

Välja jäetakse neile kriteeriumitele vastavad allikad:

- rasedusaegset diabeeti käsitlevad uuringud
- uuringud, mis ei käsitle kliinilises küsimuses toodud tulemusnäitajaid
- alfaglükosidaasi inhibiitoreid, GLP-1 analooge peamiste võrdlusravimitena

Sirveotsinguga (*hand search*) leitud artiklid: 3



Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus nr 2 (eluvii): *Kas kõigil ravinaiivsetel 2. tüüpi diabeeti põdevatel inimestel alustada ravi elustiilisekkumisega või suukaudse antidiabeetilise ravimiga või mõlemaga, parema ravitulemuse saamiseks?*

Kuupäev (pp.kk.aasta)	24.08.2020
Otsingu läbiviija	Urmeli Katus
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	<pre>((((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND (aged[Title/Abstract] OR adult*[Title/Abstract] OR "Adult"[Mesh])) AND (drug-naive[Title/Abstract] OR drug naive[Title/Abstract] OR treatment- naive[Title/Abstract] OR treatment naive[Title/Abstract] OR first line treatment OR ((initial OR initiation OR initiating OR initiate) AND (regimen OR treatment)))) AND (nutrition</pre>

	<p>program*[Title/Abstract] OR nutrition modif*[Title/Abstract] OR nutrition change*[Title/Abstract] OR nutrition intervention*[Title/Abstract] OR dietary modification*[Title/Abstract] OR diet modification*[Title/Abstract] OR diet*[Title/Abstract] OR life style program*[Title/Abstract] OR life style modif*[Title/Abstract] OR life style change*[Title/Abstract] OR life style intervention*[Title/Abstract] OR lifestyle program*[Title/Abstract] OR lifestyle modif*[Title/Abstract] OR lifestyle change*[Title/Abstract] OR lifestyle intervention*[Title/Abstract] OR "Exercise Therapy"[Mesh] OR "Exercise"[Mesh] OR "Diet Therapy"[Mesh] OR "Diet"[Mesh] OR "Healthy Lifestyle"[Mesh:NoExp] OR "Life Style"[Mesh:NoExp])) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])</p>
Tulemuste arv	42
Andmebaasi filtrid	-
Ajaline piirang (ilmumisaeg)	-
Muud piirangud	-
Märkused	<p><u>Kaasati neli süstemaatilist ülevaadet ja meta-analüüsi</u>: Umpierre et al. 2011 (füüsiline aktiivsus, ESC/EASD 2019), Franz et al. 2015 (elustiilisekkumine kehakaalu langetamiseks, ESC/EASD 2019 & süstemaatiline otsing), Craddock et al 2017 (toitumisalane sekkumine, süstemaatiline otsing), Ontario Health Technology Assessment Series 2009 (käitumuslikud sekkumised, süstemaatiline otsing)</p>

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Sihtrühmaks on 2. tüüpi diabeeti põdevad patsiendid
- Süstemaatilised ülevaated ja meta-analüüsid
- Uuringud mis võrdlevad elustiilisekkumist farmakoloogilise ravi või kontrolliga
- Süstemaatiline ülevaade koostatud viimase 10 aasta jooksul (01.01.2009–24.08.2020)

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Uuringud millel valimi moodustavad prediabeediga inimesed
- Uuringud mille valimi moodustavad 1. tüüpi diabeeti põdevad inimesed
- Uuringud, mis võrdlevad elustiilisekkumisi omavahel (grupisiselt)

Sirveotsinguga (*hand search*) leitud artiklid: -

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 33

Täistekstide põhjal välja jäetud allikad: 6

1. Livesey G, Taylor R, Livesey HF, et al. Dietary Glycemic Index and Load and the Risk of Type 2 Diabetes: A Systematic Review and Updated Meta-Analyses of Prospective Cohort Studies. *Nutrients*. 2019;11(6):1280. Published 2019 Jun 5. doi:10.3390/nu11061280. Valimis ei ole 2. tüüpi diabeeti põdevad patsiendid.
2. Ekong G, Kavookjian J. Motivational interviewing and outcomes in adults with type 2 diabetes: A systematic review. *Patient Educ Couns*. 2016;99(6):944-952. doi:10.1016/j.pec.2015.11.022. Ainult süstemaatiline ülevaade, pole meta-analüüsi.
3. Shrestha A, Karmacharya BM, Khudyakov P, Weber MB, Spiegelman D. Dietary interventions to prevent and manage diabetes in worksite settings: a meta-analysis. *J Occup Health*. 2018;60(1):31-45. doi:10.1539/joh.17-0121-RA. Valimis pole ainult 2. tüüpi diabeeti põdevad inimesed.
4. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. *Diabetes Care*. 2002;25(7):1159-1171. doi:10.2337/diacare.25.7.1159. Koostatud 2002.
5. Avenell A, Robertson C, Skea Z, et al. Bariatric surgery, lifestyle interventions and orlistat for severe obesity: the REBALANCE mixed-methods systematic review and economic evaluation [published correction appears in Health Technol Assess. 2020 May;22(68):247-250]. *Health Technol Assess*. 2018;22(68):1-246. doi:10.3310/hta22680. Võrdleb omavahel juba erinevaid dieete.
6. Nield L, Moore HJ, Hooper L, et al. Dietary advice for treatment of type 2 diabetes mellitus in adults. *Cochrane Database Syst Rev*. 2007;(3):CD004097. Published 2007 Jul 18. doi:10.1002/14651858.CD004097.pub4. Võrdleb omavahel juba erinevaid dieete, koostatud 2007.

Ravijuhenditest leitud kirjed 2

Franz MJ, Boucher JL, Rutten-Ramos S, Van Wormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and metaanalysis of randomized clinical trials. *J Acad Nutr Diet* 2015;115:1447–1463 (ADA 2020, ESC/EASD 2019).

Umpierre D, Ribeiro PA, Kramer CK, Leitao CB, Zucatti AT, Azevedo MJ, Gross JL, Ribeiro JP, Schaan BD. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA* 2011;305:1790–1799 (ESC/EASD 2019).

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus nr 2 (farmakoloogiline ravi): *Kas kõigil ravinaiivsetel 2. tüüpi diabeeti põdevatel inimestel alustada ravi elustiilisekkumisega või suukaudse antidiabeetilise ravimiga või mõlemaga, parema ravitulemuse saamiseks?*

Kuupäev (pp.kk.aasta)	24.08.2020
Otsingu läbiviija	Urmeli Katus
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	<pre>(((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II</pre>

diabete*[Title/Abstract] OR type 2
 diabete*[Title/Abstract] OR "Diabetes Mellitus,
 Type 2"[Mesh]) AND (aged[Title/Abstract] OR
 adult*[Title/Abstract] OR "Adult"[Mesh])) AND
 (drug-naive[Title/Abstract] OR drug
 naive[Title/Abstract] OR treatment-
 naive[Title/Abstract] OR treatment
 naive[Title/Abstract] OR first line treatment OR
 ((initial OR initiation OR initiating OR initiate)
 AND (regimen OR treatment)))) AND
 (jardiance*[Title/Abstract] OR BI-
 10773[Title/Abstract] OR BI
 10773[Title/Abstract] OR
 BI10773[Title/Abstract] OR
 empagliflozin*[Title/Abstract] OR
 forxiga*[Title/Abstract] OR BMS-
 512148[Title/Abstract] OR BMS
 512148[Title/Abstract] OR
 BMS512148[Title/Abstract] OR
 dapagliflozin*[Title/Abstract] OR
 invokana*[Title/Abstract] OR
 canagliflozin*[Title/Abstract] OR
 "Canagliflozin"[Mesh] OR SGLT-2
 inhibitor*[Title/Abstract] OR SGLT 2
 inhibitor*[Title/Abstract] OR SGLT2
 inhibitor*[Title/Abstract] OR
 gliflozin*[Title/Abstract] OR sodium glucose
 cotransporter 2 inhibitor*[Title/Abstract] OR
 sodium glucose co transporter 2
 inhibitor*[Title/Abstract] OR sodium glucose co-
 transporter 2 inhibitor*[Title/Abstract] OR
 sodium glucose transporter 2
 inhibitor*[Title/Abstract] OR "Sodium-Glucose
 Transporter 2 Inhibitors"[Mesh] OR
 oltar*[Title/Abstract] OR
 amarel*[Title/Abstract] OR
 amaryl*[Title/Abstract] OR HOE-
 490[Title/Abstract] OR HOE 490[Title/Abstract]
 OR HOE490[Title/Abstract] OR
 glymepiride*[Title/Abstract] OR
 glimepiride*[Title/Abstract] OR
 glibenese*[Title/Abstract] OR
 glupitel*[Title/Abstract] OR
 ozidia*[Title/Abstract] OR
 melizide*[Title/Abstract] OR

mindiab*[Title/Abstract] OR
minidiab*[Title/Abstract] OR
glucotrol*[Title/Abstract] OR
glydiazinamide*[Title/Abstract] OR
glidiazinamid*[Title/Abstract] OR
glypidizine*[Title/Abstract] OR
minodiab*[Title/Abstract] OR K-
4024[Title/Abstract] OR K 4024[Title/Abstract]
OR K4024[Title/Abstract] OR
glipizide*[Title/Abstract] OR "Glipizide"[Mesh]
OR diaprel*[Title/Abstract] OR
diabrezide*[Title/Abstract] OR
diamicron*[Title/Abstract] OR
glyade*[Title/Abstract] OR
glyclazide*[Title/Abstract] OR S-
1702[Title/Abstract] OR S 1702[Title/Abstract]
OR S1702[Title/Abstract] OR S-
852[Title/Abstract] OR S 852[Title/Abstract] OR
S852[Title/Abstract] OR
gliclazide*[Title/Abstract] OR "Gliclazide"[Mesh]
OR sulphonylurea*[Title/Abstract] OR
sulfonylureas*[Title/Abstract] OR "Sulfonylurea
Compounds"[Mesh:NoExp] OR AD
4833[Title/Abstract] OR AD-4833[Title/Abstract]
OR AD4833[Title/Abstract] OR
actos*[Title/Abstract] OR
pioglitazone*[Title/Abstract] OR
TZD[Title/Abstract] OR
glitazone*[Title/Abstract] OR
thiazolidinedione*[Title/Abstract] OR
"Pioglitazone"[Mesh] OR
"Thiazolidinediones"[Mesh:NoExp] OR
vipidia*[Title/Abstract] OR
nesina*[Title/Abstract] OR SYR-
322[Title/Abstract] OR SYR322[Title/Abstract]
OR SYR 322[Title/Abstract] OR
alogliptin*[Title/Abstract] OR
galvus*[Title/Abstract] OR LAF-
237[Title/Abstract] OR LAF237[Title/Abstract]
OR LAF 237[Title/Abstract] OR
vildagliptin[Title/Abstract] OR
"Vildagliptin"[Mesh] OR
tradjenta*[Title/Abstract] OR
trajenta*[Title/Abstract] OR BI-
1356[Title/Abstract] OR BI 1356[Title/Abstract]

	<p>OR BI1356[Title/Abstract] OR linagliptin*[Title/Abstract] OR "Linagliptin"[Mesh] OR onglyza*[Title/Abstract] OR BMS-477118[Title/Abstract] OR BMS477118[Title/Abstract] OR BMS 477118[Title/Abstract] OR saxagliptin*[Title/Abstract] OR januvia*[Title/Abstract] OR MK- 0431[Title/Abstract] OR MK0431[Title/Abstract] OR MK 0431[Title/Abstract] OR sitagliptin*[Title/Abstract] OR "Sitagliptin Phosphate"[Mesh:NoExp] OR gliptin*[Title/Abstract] OR dpp IV inhibitor*[Title/Abstract] OR dpp 4 inhibitor*[Title/Abstract] OR dipeptidylpeptidase IV inhibitor*[Title/Abstract] OR dipeptidylpeptidase 4 inhibitor*[Title/Abstract] OR dipeptidyl peptidase IV inhibitor*[Title/Abstract] OR dipeptidyl peptidase 4 inhibitor*[Title/Abstract] OR "Dipeptidyl-Peptidase IV Inhibitors"[Mesh] OR metformin*[Title/Abstract] OR "Metformin"[Mesh:NoExp])) AND ("Meta- Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])</p>
Tulemuste arv	59
Andmebaasi filtrid	-
Ajaline piirang (ilmumisaeg)	-
Muud piirangud	-
Märkused	Kaasati kaks süstemaatilist ülevaadet ja meta- analüüs: Tsapas et al. 2020 ja Genesis et al. 2020

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Sihtrühmaks on 2. tüüpi diabeeti põdevad patsiendid
- Tegemist ravinaivsete patsientidega
- Süstemaatilised-ülevaadet ja meta-analüüsid mis kaasavad RCT-sid

- Süstemaatilised ülevaated ja meta-analüüsid mis pole vanemad kui 10 aastat (01.01.2009–24.08.2020)

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Uuringud millel valimi moodustavad prediabeediga inimesed
- Uuringud mille valimi moodustavad 1. tüüpi diabeeti põdevad inimesed
- Tegemist ei ole ravinaivsete inimestega
- Süstemaatilised ülevaated ja-metaanalüüsid kuhu on kaasatud jälgimisuuringuid

Sirveotsinguga (*hand search*) leitud artiklid: -

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 46

Täistekstide põhjal raportist välja jäetud allikad: (arv põhjuste kaupa): 11

1. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. *Health Technol Assess.* 2004 May;8(21):iii-iv, 1-182. doi: 10.3310/hta8210. PMID: 15147610. Ilmunud 2004
2. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. *Diabetes Care.* 2010 Aug;33(8):1859-64. doi: 10.2337/dc09-1727. Epub 2010 May 18. PMID: 20484130; PMCID: PMC2909079. Kaasatud RCT-dest 17-ne valim koosnes ravinaivsetest uuritavates, ainult ravinaivsete uuritavate kohta eraldi alarühmade analüüsi polnud teostatud.
3. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. *Cardiovasc Diabetol.* 2012 Jan 16;11:6. doi: 10.1186/1475-2840-11-6. PMID: 22248301; PMCID: PMC3277488. metanalüüsis pole ainult platsebo võrdlus
4. Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH, Almdal T. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2013 Apr 30;(4):CD009008. doi: 10.1002/14651858.CD009008.pub2. Ei olnud ainult ravinaivsed uuritavad
5. Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. *Drug Saf.* 2014 Oct;37(10):815-29. doi: 10.1007/s40264-014-0213-4. PMID: 25096959. Kaasatud ka Kardiovaskulaarse riskiga uuritavad
6. Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, Hehnke U, Woerle HJ, von Eynatten M. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. *Am*

J Kidney Dis. 2015 Sep;66(3):441-9. doi: 10.1053/j.ajkd.2015.03.024. Epub 2015 May 7. PMID: 25960304. Kõik uuritavad polnud ravinaivsed

7. Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. JAMA. 2016 Jul 19;316(3):313-24. doi: 10.1001/jama.2016.9400. PMID: 27434443. Kõik uuritavad pole ravinaivsed, puudub info

8. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017 Sep;60(9):1620-1629. doi: 10.1007/s00125-017-4337-9. Epub 2017 Aug 2. PMID: 28770324; PMCID: PMC5552849. pole monoterapia

9. Seidu S, Kunutsor SK, Cos X, Gillani S, Khunti K; For and on behalf of Primary Care Diabetes Europe. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Prim Care Diabetes. 2018 Jun;12(3):265-283. doi: 10.1016/j.pcd.2018.02.001. Epub 2018 Feb 24. PMID: 29482993. Kõik uuritavad pole ravinaivsed

10. Cintra R, Moura FA, Carvalho LSF, Barreto J, Tambascia M, Pecoits-Filho R, Sposito AC. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Rev Assoc Med Bras (1992). 2019 Jan;65(1):70-86. doi: 10.1590/1806-9282.65.1.70. PMID: 30758423. Pole ainult võrdlus platseeboga

11. Grenet G, Ribault S, Nguyen GB, Glais F, Metge A, Linet T, Kassai-Koupai B, Cornu C, Bejan-Angoulvant T, Erpeldinger S, Boussageon R, Gouraud A, Bonnet F, Cucherat M, Moulin P, Gueyffier F. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis. PLoS One. 2019 Jun 25;14(6):e0217701. doi: 10.1371/journal.pone.0217701. PMID: 31237921; PMCID: PMC6592598. Kontrollrühma hulka kategoriseeritud ka aktiivne kontroll

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus nr 3: *Kas kõigil südame-veresoonkonna haiguse riskita ravinaiivsetel 2. tüüpi diabeeti põdevatel inimestel kasutada farmakoloogilise ravi alustamisel metformiini või sulfonüüluurea preparaati või glitasooni või DPP4 inhibiitorit või SGLT2 inhibiitorit või GLP1 agonisti parema ravitulemuse saamiseks?*

Kuupäev (pp.kk.aasta)	17.10.2020
Otsingu läbiviija	Helena Lepassar
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	<pre>((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND (drug-naive[Title/Abstract] OR drug naive[Title/Abstract] OR treatment- naive[Title/Abstract] OR treatment naive[Title/Abstract] OR first line treatment OR ((initial OR initiation OR initiating OR initiate) AND (regimen OR treatment)))) AND ((metformin*[Title/Abstract] OR</pre>

"Metformin"[Mesh:NoExp]) AND
(jardiance*[Title/Abstract] OR BI-
10773[Title/Abstract] OR BI
10773[Title/Abstract] OR
BI10773[Title/Abstract] OR
empagliflozin*[Title/Abstract] OR
forxiga*[Title/Abstract] OR BMS-
512148[Title/Abstract] OR BMS
512148[Title/Abstract] OR
BMS512148[Title/Abstract] OR
dapagliflozin*[Title/Abstract] OR
invokana*[Title/Abstract] OR
canagliflozin*[Title/Abstract] OR
"Canagliflozin"[Mesh] OR SGLT-2
inhibitor*[Title/Abstract] OR SGLT 2
inhibitor*[Title/Abstract] OR SGLT2
inhibitor*[Title/Abstract] OR
gliflozin*[Title/Abstract] OR sodium glucose
cotransporter 2 inhibitor*[Title/Abstract] OR
sodium glucose co transporter 2
inhibitor*[Title/Abstract] OR sodium glucose co-
transporter 2 inhibitor*[Title/Abstract] OR
sodium glucose transporter 2
inhibitor*[Title/Abstract] OR "Sodium-Glucose
Transporter 2 Inhibitors"[Mesh] OR
oltar*[Title/Abstract] OR
amarel*[Title/Abstract] OR
amaryl*[Title/Abstract] OR HOE-
490[Title/Abstract] OR HOE 490[Title/Abstract]
OR HOE490[Title/Abstract] OR
glymepiride*[Title/Abstract] OR
glimepiride*[Title/Abstract] OR
glibenese*[Title/Abstract] OR
glupitel*[Title/Abstract] OR
ozidia*[Title/Abstract] OR
melizide*[Title/Abstract] OR
mindiab*[Title/Abstract] OR
minidiab*[Title/Abstract] OR
glucotrol*[Title/Abstract] OR
glydiazinamide*[Title/Abstract] OR
glidiazinamid*[Title/Abstract] OR
glypidizine*[Title/Abstract] OR
minodiab*[Title/Abstract] OR K-
4024[Title/Abstract] OR K 4024[Title/Abstract]
OR K4024[Title/Abstract] OR

glipizide*[Title/Abstract] OR "Glipizide"[Mesh]
OR diaprel*[Title/Abstract] OR
diabrezide*[Title/Abstract] OR
diamicron*[Title/Abstract] OR
glyade*[Title/Abstract] OR
glyclazide*[Title/Abstract] OR S-
1702[Title/Abstract] OR S 1702[Title/Abstract]
OR S1702[Title/Abstract] OR S-
852[Title/Abstract] OR S 852[Title/Abstract] OR
S852[Title/Abstract] OR
gliclazide*[Title/Abstract] OR "Gliclazide"[Mesh]
OR sulphonylurea*[Title/Abstract] OR
sulfonylureas*[Title/Abstract] OR "Sulfonylurea
Compounds"[Mesh:NoExp] OR AD
4833[Title/Abstract] OR AD-4833[Title/Abstract]
OR AD4833[Title/Abstract] OR
actos*[Title/Abstract] OR
pioglitazone*[Title/Abstract] OR
TZD[Title/Abstract] OR
glitazone*[Title/Abstract] OR
thiazolidinedione*[Title/Abstract] OR
"Pioglitazone"[Mesh] OR
"Thiazolidinediones"[Mesh:NoExp] OR
vipidia*[Title/Abstract] OR
nesina*[Title/Abstract] OR SYR-
322[Title/Abstract] OR SYR322[Title/Abstract]
OR SYR 322[Title/Abstract] OR
alogliptin*[Title/Abstract] OR
galvus*[Title/Abstract] OR LAF-
237[Title/Abstract] OR LAF237[Title/Abstract]
OR LAF 237[Title/Abstract] OR
vildagliptin[Title/Abstract] OR
"Vildagliptin"[Mesh] OR
tradjenta*[Title/Abstract] OR
trajenta*[Title/Abstract] OR BI-
1356[Title/Abstract] OR BI 1356[Title/Abstract]
OR BI1356[Title/Abstract] OR
linagliptin*[Title/Abstract] OR
"Linagliptin"[Mesh] OR onglyza*[Title/Abstract]
OR BMS-477118[Title/Abstract] OR
BMS477118[Title/Abstract] OR BMS
477118[Title/Abstract] OR
saxagliptin*[Title/Abstract] OR
januvia*[Title/Abstract] OR MK-
0431[Title/Abstract] OR MK0431[Title/Abstract]

OR MK 0431[Title/Abstract] OR
sitagliptin*[Title/Abstract] OR "Sitagliptin
Phosphate"[Mesh:NoExp] OR
gliptin*[Title/Abstract] OR dpp IV
inhibitor*[Title/Abstract] OR dpp 4
inhibitor*[Title/Abstract] OR
dipeptidylpeptidase IV inhibitor*[Title/Abstract]
OR dipeptidylpeptidase 4
inhibitor*[Title/Abstract] OR dipeptidyl
peptidase IV inhibitor*[Title/Abstract] OR
dipeptidyl peptidase 4 inhibitor*[Title/Abstract]
OR "Dipeptidyl-Peptidase IV Inhibitors"[Mesh]
OR NN-9924[Title/Abstract] OR
NN9924[Title/Abstract] OR
NN9535[Title/Abstract] OR NN-
9535[Title/Abstract] OR
Semaglutide[Title/Abstract] OR AC
2993[Title/Abstract] OR Exendin
4[Title/Abstract] OR Peptide, Ex4[Title/Abstract]
OR Ex4 Peptide[Title/Abstract] OR Exendin-
4[Title/Abstract] OR AC 2993 LAR[Title/Abstract]
OR ITCA 650[Title/Abstract] OR
Bydureon[Title/Abstract] OR
Exenatide[Title/Abstract] OR
Trulicity[Title/Abstract] OR
LY2189265[Title/Abstract] OR LY-
2189265[Title/Abstract] OR LY
2189265[Title/Abstract] OR
Dulaglutide[Title/Abstract] OR AVE-
0010[Title/Abstract] OR AVE0010[Title/Abstract]
OR AVE 0010[Title/Abstract] OR AVE-
010[Title/Abstract] OR AVE 010[Title/Abstract]
OR Lyxumia[Title/Abstract] OR ZP-
10[Title/Abstract] OR ZP 10[Title/Abstract] OR
ZP10A peptide[Title/Abstract] OR AQVE-
10010[Title/Abstract] OR Adlyxin[Title/Abstract]
OR Lixisenatide[Title/Abstract] OR NN-
2211[Title/Abstract] OR NN2211[Title/Abstract]
OR NN 2211[Title/Abstract] OR
Saxenda[Title/Abstract] OR
Victoza[Title/Abstract] OR
Liraglutide[Title/Abstract] OR "semaglutide"
[Supplementary Concept] OR "Exenatide"[Mesh]
OR "dulaglutide" [Supplementary Concept] OR
"lixisenatide" [Supplementary Concept] OR

	"Liraglutide"[Mesh] OR "Glucagon-Like Peptide-1 Receptor"[Mesh] OR "Glucagon-Like Peptide 1"[Mesh])) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])
Tulemuste arv	64
Andmebaasi filtrid	–
Ajaline piirang (ilmumisaeg)	Alates 01.01.2009
Muud piirangud	–

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Sihtrühm: 2. tüüpi diabeedi patsiendid
- Patsiendid ravinaiivsed ja madala kardiovaskulaarse riskiga
- Inglisekeelsed artiklid
- Ainult RCTd

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Valimis ka 1. tüüpi diabeediga patsiendid
- Kardiovaskulaarse riskiga patsiendid
- Kombineeritud ravi mitme preparaadiga

Sirveotsinguga (*hand search*) leitud artiklid: 0

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 60

Täistekstide põhjal raportist välja jäetud allikad: (arv põhjuste kaupa)

1. Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. JAMA. 2016 Jul 19;316(3):313-24. doi: 10.1001/jama.2016.9400. PMID: 27434443. Uemas raportis (2020. aasta Tsapas) sarnased tulemusnäitajad ja tulemused.
2. Jia Y, Lao Y, Zhu H, Li N, Leung SW. Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials. Obes Rev. 2019 Jan;20(1):1-12. doi: 10.1111/obr.12753. Epub 2018 Sep 17.

PMID: 30230172. Käsitleb tulemusnäitajana ainult glükoosiväärtusi, teisi tulemusnäitajaid kaasatud ei ole.

Kaasatud raportid:

1. Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. *Ann Intern Med.* 2020 Aug 18;173(4):278-286. doi: 10.7326/M20-0864. Epub 2020 Jun 30. PMID: 32598218.
2. Gnesin F, Thuesen ACB, Kähler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2. PMID: 32501595; PMCID: PMC7386876.

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus nr 4: *Kas kõigil südame-veresoonkonna haiguse riskiga või olemasoleva südame-veresoonkonna haigusega 2. tüüpi diabeeti põdevatel inimestel kasutada ravi alustamisel metformiini või sulfonüüluurea preparaati või glitasooni või DPP4 inhibiitorit või SGLT2 inhibiitorit või GLP1 agonisti parema ravitulemuse saamiseks?*

Kuupäev (pp.kk.aasta)	14.11.2020
Otsingu läbiviija	Helena Lepassar
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	<pre>((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non- insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND ((jardiance*[Title/Abstract] OR BI-10773[Title/Abstract] OR BI 10773[Title/Abstract] OR BI10773[Title/Abstract] OR empagliflozin*[Title/Abstract] OR forxiga*[Title/Abstract] OR BMS-</pre>

512148[Title/Abstract] OR BMS
512148[Title/Abstract] OR
BMS512148[Title/Abstract] OR
dapagliflozin*[Title/Abstract] OR
invokana*[Title/Abstract] OR
canagliflozin*[Title/Abstract] OR
"Canagliflozin"[Mesh] OR SGLT-2
inhibitor*[Title/Abstract] OR SGLT 2
inhibitor*[Title/Abstract] OR SGLT2
inhibitor*[Title/Abstract] OR
gliflozin*[Title/Abstract] OR sodium glucose
cotransporter 2 inhibitor*[Title/Abstract] OR
sodium glucose co transporter 2
inhibitor*[Title/Abstract] OR sodium glucose co-
transporter 2 inhibitor*[Title/Abstract] OR
sodium glucose transporter 2
inhibitor*[Title/Abstract] OR "Sodium-Glucose
Transporter 2 Inhibitors"[Mesh] OR
oltar*[Title/Abstract] OR amarel*[Title/Abstract]
OR amaryl*[Title/Abstract] OR HOE-
490[Title/Abstract] OR HOE 490[Title/Abstract]
OR HOE490[Title/Abstract] OR
glymepiride*[Title/Abstract] OR
glimepiride*[Title/Abstract] OR
glibenese*[Title/Abstract] OR
glupitel*[Title/Abstract] OR
ozidia*[Title/Abstract] OR
melizide*[Title/Abstract] OR
mindiab*[Title/Abstract] OR
minidiab*[Title/Abstract] OR
glucotrol*[Title/Abstract] OR
glydiazinamide*[Title/Abstract] OR
glidiazinamid*[Title/Abstract] OR
glypidizine*[Title/Abstract] OR
minodiab*[Title/Abstract] OR K-
4024[Title/Abstract] OR K 4024[Title/Abstract]
OR K4024[Title/Abstract] OR
glipizide*[Title/Abstract] OR "Glipizide"[Mesh]
OR diaprel*[Title/Abstract] OR
diabrezide*[Title/Abstract] OR
diamicron*[Title/Abstract] OR
glyade*[Title/Abstract] OR
glyclazide*[Title/Abstract] OR S-
1702[Title/Abstract] OR S 1702[Title/Abstract]

OR S1702[Title/Abstract] OR S-
852[Title/Abstract] OR S 852[Title/Abstract] OR
S852[Title/Abstract] OR
gliclazide*[Title/Abstract] OR "Gliclazide"[Mesh]
OR sulphonylurea*[Title/Abstract] OR
sulfonylureas*[Title/Abstract] OR "Sulfonylurea
Compounds"[Mesh:NoExp] OR AD
4833[Title/Abstract] OR AD-4833[Title/Abstract]
OR AD4833[Title/Abstract] OR
actos*[Title/Abstract] OR
pioglitazone*[Title/Abstract] OR
TZD[Title/Abstract] OR glitazone*[Title/Abstract]
OR thiazolidinedione*[Title/Abstract] OR
"Pioglitazone"[Mesh] OR
"Thiazolidinediones"[Mesh:NoExp] OR
vipidia*[Title/Abstract] OR
nesina*[Title/Abstract] OR SYR-
322[Title/Abstract] OR SYR322[Title/Abstract] OR
SYR 322[Title/Abstract] OR
alogliptin*[Title/Abstract] OR
galvus*[Title/Abstract] OR LAF-
237[Title/Abstract] OR LAF237[Title/Abstract] OR
LAF 237[Title/Abstract] OR
vildagliptin[Title/Abstract] OR
"Vildagliptin"[Mesh] OR
tradjenta*[Title/Abstract] OR
trajenta*[Title/Abstract] OR BI-
1356[Title/Abstract] OR BI 1356[Title/Abstract]
OR BI1356[Title/Abstract] OR
linagliptin*[Title/Abstract] OR
"Linagliptin"[Mesh] OR onglyza*[Title/Abstract]
OR BMS-477118[Title/Abstract] OR
BMS477118[Title/Abstract] OR BMS
477118[Title/Abstract] OR
saxagliptin*[Title/Abstract] OR
januvia*[Title/Abstract] OR MK-
0431[Title/Abstract] OR MK0431[Title/Abstract]
OR MK 0431[Title/Abstract] OR
sitagliptin*[Title/Abstract] OR "Sitagliptin
Phosphate"[Mesh:NoExp] OR
gliptin*[Title/Abstract] OR dpp IV
inhibitor*[Title/Abstract] OR dpp 4
inhibitor*[Title/Abstract] OR dipeptidylpeptidase
IV inhibitor*[Title/Abstract] OR

dipeptidylpeptidase 4 inhibitor*[Title/Abstract]
 OR dipeptidyl peptidase IV
 inhibitor*[Title/Abstract] OR dipeptidyl peptidase
 4 inhibitor*[Title/Abstract] OR "Dipeptidyl-
 Peptidase IV Inhibitors"[Mesh] OR
 metformin*[Title/Abstract] OR
 "Metformin"[Mesh:NoExp]) OR (NN-
 9924[Title/Abstract] OR NN9924[Title/Abstract]
 OR NN9535[Title/Abstract] OR NN-
 9535[Title/Abstract] OR
 Semaglutide[Title/Abstract] OR AC
 2993[Title/Abstract] OR Exendin 4[Title/Abstract]
 OR Peptide, Ex4[Title/Abstract] OR Ex4
 Peptide[Title/Abstract] OR Exendin-
 4[Title/Abstract] OR AC 2993 LAR[Title/Abstract]
 OR ITCA 650[Title/Abstract] OR
 Bydureon[Title/Abstract] OR
 Exenatide[Title/Abstract] OR
 Trulicity[Title/Abstract] OR
 LY2189265[Title/Abstract] OR LY-
 2189265[Title/Abstract] OR LY
 2189265[Title/Abstract] OR
 Dulaglutide[Title/Abstract] OR AVE-
 0010[Title/Abstract] OR AVE0010[Title/Abstract]
 OR AVE 0010[Title/Abstract] OR AVE-
 010[Title/Abstract] OR AVE 010[Title/Abstract]
 OR Lyxumia[Title/Abstract] OR ZP-
 10[Title/Abstract] OR ZP 10[Title/Abstract] OR
 ZP10A peptide[Title/Abstract] OR AQVE-
 10010[Title/Abstract] OR Adlyxin[Title/Abstract]
 OR Lixisenatide[Title/Abstract] OR NN-
 2211[Title/Abstract] OR NN2211[Title/Abstract]
 OR NN 2211[Title/Abstract] OR
 Saxenda[Title/Abstract] OR
 Victoza[Title/Abstract] OR
 Liraglutide[Title/Abstract] OR "semaglutide"
 [Supplementary Concept] OR "Exenatide"[Mesh]
 OR "dulaglutide" [Supplementary Concept] OR
 "lixisenatide" [Supplementary Concept] OR
 "Liraglutide"[Mesh] OR "Glucagon-Like Peptide-1
 Receptor"[Mesh] OR "Glucagon-Like Peptide
 1"[Mesh])))) AND ("Cardiovascular
 Diseases"[Mesh:NoExp] OR "Myocardial
 Infarction"[Mesh:NoExp] OR "Myocardial

	Ischemia"[Mesh:NoExp] OR "Ventricular Dysfunction"[Mesh:NoExp] OR cardiovascular[Title/Abstract] OR cardiac[Title/Abstract] OR myocardial[Title/Abstract] OR heart failure[Title/Abstract] OR "Heart Failure"[Mesh])) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])
Tulemuste arv	373
Andmebaasi filtrid	Inglise keel, inimesed
Ajaline piirang (ilmumisaeg)	Alates 01.01.2009
Muud piirangud	
Märkused	

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Sihtrühm: 2. tüüpi diabeedi patsiendid
- Inglisekeelsed artiklid
- Ainult inimesed
- Ainult randomiseeritud kontrolluuringud

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Valimis ka 1. tüüpi diabeediga patsiendid
- Kohortuuringud
- Uuringud, mis käsitlevad GLP-1 agoniste ja SGLT2 inhibiitoreid

Sirveotsinguga (*hand search*) leitud artiklid: 0

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 368

Täistekstide põhjal raportist välja jäetud allikad: (arv põhjuste kaupa)

1. Lee G, Oh SW, Hwang SS, et al. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. *PLoS One*. 2017;12(5):e0177646. Published 2017 May 25. doi:10.1371/journal.pone.0177646. Uuemas metaanalüüsis ja süstemaatilises ülevaates samad tulemusnäitajad.
2. Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab*. 2013 Feb;15(2):112-20. doi: 10.1111/dom.12000. Epub 2012 Sep 20. PMID: 22925682. Puudub võrdlus metformiiniga

Kaasatud:

1. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. *Diabetologia*. 2017 Sep;60(9):1620-1629. doi: 10.1007/s00125-017-4337-9. Epub 2017 Aug 2. PMID: 28770324; PMCID: PMC5552849.
2. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab*. 2013 Oct;15(10):938-53. doi: 10.1111/dom.12116. Epub 2013 May 13. PMID: 23594109.
3. Grenet G, Ribault S, Nguyen GB, et al. GLUcose COntrol Safety & Efficacy in type 2 Diabetes, a systematic review and NETwork meta-analysis. *PLoS One*. 2019;14(6):e0217701. Published 2019 Jun 25. doi:10.1371/journal.pone.0217701

Kuna tõendust metformiin vs. teine aktiivne diabeedi ravim kohta oli vähe vaatas Urmeli Katus kirjed (01.01.2020–18.11.2020) uuesti üle ja kaasas veel kaks uuringut (jälgimisuuringuid kaasavad metaanalüüsid):

1. Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. *Cardiovasc Diabetol*. 2019 Jul 30;18(1):96.
2. Pladevall M, Riera-Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S. Cardiovascular risk associated with the use of glitazones, metformin and sulfonylureas: meta-analysis of published observational studies. *BMC Cardiovasc Disord*. 2016 Jan 15;16:14.

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus nr 4: *Kas kõigil südame-veresoonkonna haiguse riskiga või olemasoleva südame-veresoonkonna haigusega 2. tüüpi diabeeti põdevatel inimestel kasutada ravi alustamisel metformiini või sulfonüüluurea preparaati või glitasooni või DPP4 inhibiitorit või SGLT2 inhibiitorit või GLP1 agonisti parema ravitulemuse saamiseks?*

Kuupäev (pp.kk.aasta)	20.11.2020
Otsingu läbiviija	Urmeli Katus
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	<pre>((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND ("Cardiovascular Diseases"[Mesh:NoExp] OR "Myocardial Infarction"[Mesh:NoExp] OR "Myocardial Ischemia"[Mesh:NoExp] OR "Ventricular Dysfunction"[Mesh:NoExp] OR cardiovascular[Title/Abstract] OR cardiac[Title/Abstract] OR</pre>

myocardial[Title/Abstract] OR heart failure[Title/Abstract] OR "Heart Failure"[Mesh])) AND ((metformin*[Title/Abstract] OR "Metformin"[Mesh:NoExp]) AND ((jardiance*[Title/Abstract] OR BI-10773[Title/Abstract] OR BI10773[Title/Abstract] OR empagliflozin*[Title/Abstract] OR forxiga*[Title/Abstract] OR BMS-512148[Title/Abstract] OR BMS512148[Title/Abstract] OR dapagliflozin*[Title/Abstract] OR invokana*[Title/Abstract] OR canagliflozin*[Title/Abstract] OR "Canagliflozin"[Mesh] OR SGLT-2 inhibitor*[Title/Abstract] OR SGLT 2 inhibitor*[Title/Abstract] OR SGLT2 inhibitor*[Title/Abstract] OR glibenese*[Title/Abstract] OR sodium glucose cotransporter 2 inhibitor*[Title/Abstract] OR sodium glucose co transporter 2 inhibitor*[Title/Abstract] OR sodium glucose co-transporter 2 inhibitor*[Title/Abstract] OR sodium glucose transporter 2 inhibitor*[Title/Abstract] OR "Sodium-Glucose Transporter 2 Inhibitors"[Mesh] OR oltar*[Title/Abstract] OR amarel*[Title/Abstract] OR amaryl*[Title/Abstract] OR HOE-490[Title/Abstract] OR HOE 490[Title/Abstract] OR HOE490[Title/Abstract] OR glymepiride*[Title/Abstract] OR glimepiride*[Title/Abstract] OR glibenese*[Title/Abstract] OR glupitel*[Title/Abstract] OR ozidia*[Title/Abstract] OR melizide*[Title/Abstract] OR mindiab*[Title/Abstract] OR minidiab*[Title/Abstract] OR glucotrol*[Title/Abstract] OR glydiazinamide*[Title/Abstract] OR glidiazinamid*[Title/Abstract] OR

glypidizine*[Title/Abstract] OR
minodiab*[Title/Abstract] OR K-
4024[Title/Abstract] OR K 4024[Title/Abstract]
OR K4024[Title/Abstract] OR
glipizide*[Title/Abstract] OR "Glipizide"[Mesh]
OR diaprel*[Title/Abstract] OR
diabrezide*[Title/Abstract] OR
diamicron*[Title/Abstract] OR
glyade*[Title/Abstract] OR
glyclazide*[Title/Abstract] OR S-
1702[Title/Abstract] OR S 1702[Title/Abstract]
OR S1702[Title/Abstract] OR S-
852[Title/Abstract] OR S 852[Title/Abstract] OR
S852[Title/Abstract] OR
gliclazide*[Title/Abstract] OR "Gliclazide"[Mesh]
OR sulphonylurea*[Title/Abstract] OR
sulfonylureas*[Title/Abstract] OR "Sulfonylurea
Compounds"[Mesh:NoExp] OR AD
4833[Title/Abstract] OR AD-4833[Title/Abstract]
OR AD4833[Title/Abstract] OR
actos*[Title/Abstract] OR
pioglitazone*[Title/Abstract] OR
TZD[Title/Abstract] OR
glitazone*[Title/Abstract] OR
thiazolidinedione*[Title/Abstract] OR
"Pioglitazone"[Mesh] OR
"Thiazolidinediones"[Mesh:NoExp] OR
vipidia*[Title/Abstract] OR
nesina*[Title/Abstract] OR SYR-
322[Title/Abstract] OR SYR322[Title/Abstract]
OR SYR 322[Title/Abstract] OR
alogliptin*[Title/Abstract] OR
galvus*[Title/Abstract] OR LAF-
237[Title/Abstract] OR LAF237[Title/Abstract]
OR LAF 237[Title/Abstract] OR
vildagliptin[Title/Abstract] OR
"Vildagliptin"[Mesh] OR
tradjenta*[Title/Abstract] OR
trajenta*[Title/Abstract] OR BI-
1356[Title/Abstract] OR BI 1356[Title/Abstract]
OR BI1356[Title/Abstract] OR
linagliptin*[Title/Abstract] OR
"Linagliptin"[Mesh] OR onglyza*[Title/Abstract]
OR BMS-477118[Title/Abstract] OR
BMS477118[Title/Abstract] OR BMS

477118[Title/Abstract] OR
saxagliptin*[Title/Abstract] OR
januvia*[Title/Abstract] OR MK-
0431[Title/Abstract] OR MK0431[Title/Abstract]
OR MK 0431[Title/Abstract] OR
sitagliptin*[Title/Abstract] OR "Sitagliptin
Phosphate"[Mesh:NoExp] OR
gliptin*[Title/Abstract] OR dpp IV
inhibitor*[Title/Abstract] OR dpp 4
inhibitor*[Title/Abstract] OR
dipeptidylpeptidase IV inhibitor*[Title/Abstract]
OR dipeptidylpeptidase 4
inhibitor*[Title/Abstract] OR dipeptidyl
peptidase IV inhibitor*[Title/Abstract] OR
dipeptidyl peptidase 4 inhibitor*[Title/Abstract]
OR "Dipeptidyl-Peptidase IV Inhibitors"[Mesh])
OR (NN-9924[Title/Abstract] OR
NN9924[Title/Abstract] OR
NN9535[Title/Abstract] OR NN-
9535[Title/Abstract] OR
Semaglutide[Title/Abstract] OR AC
2993[Title/Abstract] OR Exendin
4[Title/Abstract] OR Peptide, Ex4[Title/Abstract]
OR Ex4 Peptide[Title/Abstract] OR Exendin-
4[Title/Abstract] OR AC 2993 LAR[Title/Abstract]
OR ITCA 650[Title/Abstract] OR
Bydureon[Title/Abstract] OR
Exenatide[Title/Abstract] OR
Trulicity[Title/Abstract] OR
LY2189265[Title/Abstract] OR LY-
2189265[Title/Abstract] OR LY
2189265[Title/Abstract] OR
Dulaglutide[Title/Abstract] OR AVE-
0010[Title/Abstract] OR AVE0010[Title/Abstract]
OR AVE 0010[Title/Abstract] OR AVE-
010[Title/Abstract] OR AVE 010[Title/Abstract]
OR Lyxumia[Title/Abstract] OR ZP-
10[Title/Abstract] OR ZP 10[Title/Abstract] OR
ZP10A peptide[Title/Abstract] OR AQVE-
10010[Title/Abstract] OR Adlyxin[Title/Abstract]
OR Lixisenatide[Title/Abstract] OR NN-
2211[Title/Abstract] OR NN2211[Title/Abstract]
OR NN 2211[Title/Abstract] OR
Saxenda[Title/Abstract] OR
Victoza[Title/Abstract] OR

	Liraglutide[Title/Abstract] OR "semaglutide" [Supplementary Concept] OR "Exenatide"[Mesh] OR "dulaglutide" [Supplementary Concept] OR "lixisenatide" [Supplementary Concept] OR "Liraglutide"[Mesh] OR "Glucagon-Like Peptide-1 Receptor"[Mesh] OR "Glucagon-Like Peptide 1"[Mesh]))) AND (Randomized Controlled Trial[PT] OR Randomized Controlled Trials[MeSH] OR randomized controlled trial*[tiab] OR randomized control trial*[tiab] OR (Clinical Trial[PT] AND (Random Allocation[MeSH] OR random*[tiab] OR Double-blind Method[MeSH] OR double blind*[tiab])))
Tulemuste arv	133
Andmebaasi filtrid	Keel: English; Liik: human
Ajaline piirang (ilmumisaeg)	01.01.2014–20.11.2020
Muud piirangud	-
Märkused	Ilma ajalise piirangu ja filtritega: 348; ajalise piiranguga: 153; ajalise piirangu ja filtritega: 133

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Uuritavad on 2. tüüpi diabeeti põdevad inimesed
- Sisaldavad meile huvipakkuvaid tulemeid

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Uuringud kus valimi moodustavad preediabeeti põdevad inimesed
- Uuringud kus valimi moodustavad 1. tüüpi diabeeti põdevad inimesed

Sirveotsinguga (*hand search*) leitud artiklid: -

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 129

Täistekstide põhjal raportist välja jäetud allikad: 1

Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, Hirose T. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. *Cardiovasc Diabetol.* 2017 Jul 6;16(1):84. Lisatuna metformiinile.

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus nr 4: *Kas kõigil südame-veresoonkonna haiguse riskiga või olemasoleva südame-veresoonkonna haigusega 2. tüüpi diabeeti põdevatel inimestel kasutada ravi alustamisel metformiini või sulfonüüluurea preparaati või glitasooni või DPP4 inhibiitorit või SGLT2 inhibiitorit või GLP1 agonisti parema ravitulemuse saamiseks?*

Kuupäev (pp.kk.aasta)	20.11.2020
Otsingu läbiviija	Urmeli Katus
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	((((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND ("Cardiovascular Diseases"[Mesh:NoExp] OR "Myocardial Infarction"[Mesh:NoExp] OR "Myocardial Ischemia"[Mesh:NoExp] OR "Ventricular Dysfunction"[Mesh:NoExp] OR cardiovascular[Title/Abstract] OR cardiac[Title/Abstract] OR

myocardial[Title/Abstract] OR heart failure[Title/Abstract] OR "Heart Failure"[Mesh])) AND ((metformin*[Title/Abstract] OR "Metformin"[Mesh:NoExp]) AND ((jardiance*[Title/Abstract] OR BI-10773[Title/Abstract] OR BI-10773[Title/Abstract] OR BI10773[Title/Abstract] OR empagliflozin*[Title/Abstract] OR forxiga*[Title/Abstract] OR BMS-512148[Title/Abstract] OR BMS 512148[Title/Abstract] OR BMS512148[Title/Abstract] OR dapagliflozin*[Title/Abstract] OR invokana*[Title/Abstract] OR canagliflozin*[Title/Abstract] OR "Canagliflozin"[Mesh] OR SGLT-2 inhibitor*[Title/Abstract] OR SGLT 2 inhibitor*[Title/Abstract] OR SGLT2 inhibitor*[Title/Abstract] OR gliflozin*[Title/Abstract] OR sodium glucose cotransporter 2 inhibitor*[Title/Abstract] OR sodium glucose co transporter 2 inhibitor*[Title/Abstract] OR sodium glucose co-transporter 2 inhibitor*[Title/Abstract] OR sodium glucose transporter 2 inhibitor*[Title/Abstract] OR "Sodium-Glucose Transporter 2 Inhibitors"[Mesh] OR oltar*[Title/Abstract] OR amarel*[Title/Abstract] OR amaryl*[Title/Abstract] OR HOE-490[Title/Abstract] OR HOE 490[Title/Abstract] OR HOE490[Title/Abstract] OR glymepiride*[Title/Abstract] OR glimepiride*[Title/Abstract] OR glibenese*[Title/Abstract] OR glupitel*[Title/Abstract] OR ozidia*[Title/Abstract] OR melizide*[Title/Abstract] OR mindiab*[Title/Abstract] OR minidiab*[Title/Abstract] OR glucotrol*[Title/Abstract] OR glydiazinamide*[Title/Abstract] OR glidiazinamid*[Title/Abstract] OR

glypidizine*[Title/Abstract] OR
minodiab*[Title/Abstract] OR K-
4024[Title/Abstract] OR K 4024[Title/Abstract]
OR K4024[Title/Abstract] OR
glipizide*[Title/Abstract] OR "Glipizide"[Mesh]
OR diaprel*[Title/Abstract] OR
diabrezide*[Title/Abstract] OR
diamicron*[Title/Abstract] OR
glyade*[Title/Abstract] OR
glyclazide*[Title/Abstract] OR S-
1702[Title/Abstract] OR S 1702[Title/Abstract]
OR S1702[Title/Abstract] OR S-
852[Title/Abstract] OR S 852[Title/Abstract] OR
S852[Title/Abstract] OR
gliclazide*[Title/Abstract] OR "Gliclazide"[Mesh]
OR sulphonylurea*[Title/Abstract] OR
sulfonylureas*[Title/Abstract] OR "Sulfonylurea
Compounds"[Mesh:NoExp] OR AD
4833[Title/Abstract] OR AD-4833[Title/Abstract]
OR AD4833[Title/Abstract] OR
actos*[Title/Abstract] OR
pioglitazone*[Title/Abstract] OR
TZD[Title/Abstract] OR
glitazone*[Title/Abstract] OR
thiazolidinedione*[Title/Abstract] OR
"Pioglitazone"[Mesh] OR
"Thiazolidinediones"[Mesh:NoExp] OR
vipidia*[Title/Abstract] OR
nesina*[Title/Abstract] OR SYR-
322[Title/Abstract] OR SYR322[Title/Abstract]
OR SYR 322[Title/Abstract] OR
alogliptin*[Title/Abstract] OR
galvus*[Title/Abstract] OR LAF-
237[Title/Abstract] OR LAF237[Title/Abstract]
OR LAF 237[Title/Abstract] OR
vildagliptin[Title/Abstract] OR
"Vildagliptin"[Mesh] OR
tradjenta*[Title/Abstract] OR
trajenta*[Title/Abstract] OR BI-
1356[Title/Abstract] OR BI 1356[Title/Abstract]
OR BI1356[Title/Abstract] OR
linagliptin*[Title/Abstract] OR
"Linagliptin"[Mesh] OR onglyza*[Title/Abstract]
OR BMS-477118[Title/Abstract] OR
BMS477118[Title/Abstract] OR BMS

477118[Title/Abstract] OR
 saxagliptin*[Title/Abstract] OR
 januvia*[Title/Abstract] OR MK-
 0431[Title/Abstract] OR MK0431[Title/Abstract]
 OR MK 0431[Title/Abstract] OR
 sitagliptin*[Title/Abstract] OR "Sitagliptin
 Phosphate"[Mesh:NoExp] OR
 gliptin*[Title/Abstract] OR dpp IV
 inhibitor*[Title/Abstract] OR dpp 4
 inhibitor*[Title/Abstract] OR
 dipeptidylpeptidase IV inhibitor*[Title/Abstract]
 OR dipeptidylpeptidase 4
 inhibitor*[Title/Abstract] OR dipeptidyl
 peptidase IV inhibitor*[Title/Abstract] OR
 dipeptidyl peptidase 4 inhibitor*[Title/Abstract]
 OR "Dipeptidyl-Peptidase IV Inhibitors"[Mesh])
 OR (NN-9924[Title/Abstract] OR
 NN9924[Title/Abstract] OR
 NN9535[Title/Abstract] OR NN-
 9535[Title/Abstract] OR
 Semaglutide[Title/Abstract] OR AC
 2993[Title/Abstract] OR Exendin
 4[Title/Abstract] OR Peptide, Ex4[Title/Abstract]
 OR Ex4 Peptide[Title/Abstract] OR Exendin-
 4[Title/Abstract] OR AC 2993 LAR[Title/Abstract]
 OR ITCA 650[Title/Abstract] OR
 Bydureon[Title/Abstract] OR
 Exenatide[Title/Abstract] OR
 Trulicity[Title/Abstract] OR
 LY2189265[Title/Abstract] OR LY-
 2189265[Title/Abstract] OR LY
 2189265[Title/Abstract] OR
 Dulaglutide[Title/Abstract] OR AVE-
 0010[Title/Abstract] OR AVE0010[Title/Abstract]
 OR AVE 0010[Title/Abstract] OR AVE-
 010[Title/Abstract] OR AVE 010[Title/Abstract]
 OR Lyxumia[Title/Abstract] OR ZP-
 10[Title/Abstract] OR ZP 10[Title/Abstract] OR
 ZP10A peptide[Title/Abstract] OR AQVE-
 10010[Title/Abstract] OR Adlyxin[Title/Abstract]
 OR Lixisenatide[Title/Abstract] OR NN-
 2211[Title/Abstract] OR NN2211[Title/Abstract]
 OR NN 2211[Title/Abstract] OR
 Saxenda[Title/Abstract] OR
 Victoza[Title/Abstract] OR

	Liraglutide[Title/Abstract] OR "semaglutide" [Supplementary Concept] OR "Exenatide"[Mesh] OR "dulaglutide" [Supplementary Concept] OR "lixisenatide" [Supplementary Concept] OR "Liraglutide"[Mesh] OR "Glucagon-Like Peptide-1 Receptor"[Mesh] OR "Glucagon-Like Peptide 1"[Mesh]))) AND (Epidemiologic Studies[Mesh:NoExp] OR Case-Control Studies[Mesh] OR Cohort Studies[Mesh] OR Cross-Sectional Studies[Mesh:NoExp] OR (epidemiologic[Title/Abstract] AND (study[Title/Abstract] OR studies[Title/Abstract])) OR case control[Title/Abstract] OR (cohort[Title/Abstract] AND (study[Title/Abstract] OR studies[Title/Abstract])) OR cross sectional[Title/Abstract] OR cohort analy*[Title/Abstract] OR (follow up[Title/Abstract] AND (study[Title/Abstract] OR studies[Title/Abstract])) OR longitudinal[Title/Abstract] OR retrospective*[Title/Abstract] OR prospective*[Title/Abstract] OR (observ*[Title/Abstract] AND (study[Title/Abstract] or studies[Title/Abstract])) OR adverse effect*[Title/Abstract])
Tulemuste arv	215
Andmebaasi filtrid	Keel: English; Liik: human
Ajaline piirang (ilmumisaeg)	01.01.2014–20.11.2020
Muud piirangud	-
Märkused	Ilma ajalise piirangu ja filtritega: 348; ajalise piiranguga: 305; ajalise piirangu ja filtritega: 215

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Uuritavad on 2. tüüpi diabeeti põdevad inimesed
- Võrreldakse metformiini mõne teise aktiivse diabeedi ravimrühmaga (v.a insuliin)
- Sisaldavad meile huvipakkuvaid tulemusnäitajaid
- Inglise keelsed artiklid

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Uuritavad ei ole 2. tüüpi diabeeti põdevad inimesed
- Meile huvipakkuvaid tulemusnäitajaid ei ole raporteeritud

Sirveotsinguga (*hand search*) leitud artiklid: -

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 207

Täistekstide põhjal raportist välja jäetud allikad: 5

Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, Maratou E, Georgiou D, Andreadou I, Parissis J, Triantafyllidi H, Lekakis J, Iliodromitis E, Dimitriadis G, Ikonomidis I. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. *Cardiovasc Diabetol*. 2018 Jan 8;17(1):8. Duubel, tuli välja ka RCT otsinguga.

Wurm R, Resl M, Neuhold S, Prager R, Brath H, Francesconi C, Vila G, Strunk G, Clodi M, Luger A, Pacher R, Hülsmann M. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. *Heart*. 2016 Oct 1;102(19):1544-51. Puudus otsene võrdlus metformiini ja SU vahel.

Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. *Clin Ther*. 2016 Jun;38(6):1288-1298. Kommentaar.

Pladevall M, Riera-Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S. Cardiovascular risk associated with the use of glitazones, metformin and sulfonylureas: meta-analysis of published observational studies. *BMC Cardiovasc Disord*. 2016 Jan 15;16:14. Duubel, tuli välja ka SR ja MA otsingus.

Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. *Diabetes Obes Metab*. 2014 Oct;16(10):957-62

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliinilised küsimused nr 5–7:

Kas kõigil 2. tüüpi diabeeti põdevatel inimestel kasutada ravi esimesel intensiivistamisel metformiini või sulfonüüluurea preparaati või glitasooni või DPP4 inhibiitorit või SGLT2 inhibiitorit või GLP1 agonisti või basaalinsuliini, parema ravitulemuse saamiseks?

Kas kõigil 2. tüüpi diabeeti põdevatel inimestel kasutada ravi teisel intensiivistamisel metformiini või sulfonüüluurea preparaati või glitasooni või DPP4 inhibiitorit või SGLT2 inhibiitorit või GLP1 agonisti või basaalinsuliini, parema ravitulemuse saamiseks?

Kas kõigil 2. tüüpi diabeeti põdevatel inimestel kasutada ravi kolmandal intensiivistamisel metformiini või sulfonüüluurea preparaati või glitasooni või DPP4 inhibiitorit või SGLT2 inhibiitorit või GLP1 agonisti või basaalinsuliini, parema ravitulemuse saamiseks?

Kuupäev (pp.kk.aasta)	13.11.2020
Otsingu läbiviija	Grit Arro
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	<pre>((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2</pre>

diabete*[Title/Abstract] OR "Diabetes Mellitus,
 Type 2"[Mesh]) AND (("insulin aspart, insulin
 aspart protamine drug combination
 30:70"[Supplementary Concept] OR "insulin
 lispro, isophane insulin lispro drug combination
 (25:75)"[Supplementary Concept] OR "isophane
 insulin, insulin lispro drug combination
 50:50"[Supplementary Concept] OR "insulin
 degludec"[Supplementary Concept] OR "Insulin
 Glargine"[Mesh] OR "Insulin Detemir"[Mesh] OR
 "insulin glulisine" [Supplementary Concept] OR
 "Insulin Aspart"[Mesh] OR "Insulin
 Lispro"[Mesh] OR "Insulin, Isophane"[Mesh] OR
 "Isophane Insulin, Human"[Mesh] OR "Insulin,
 Long-Acting"[Mesh] OR "Insulin, Short-
 Acting"[Mesh] OR "Insulin, Regular,
 Human"[Mesh] OR "Insulin"[Mesh] OR humalog
 mix[Title/Abstract] OR novomix[Title/Abstract]
 OR actrapid[Title/Abstract] OR
 humulin*[Title/Abstract] OR
 novolin*[Title/Abstract] OR
 toujeo[Title/Abstract] OR lantus[Title/Abstract]
 OR levemir[Title/Abstract] OR
 tresiba[Title/Abstract] OR fiasp[Title/Abstract]
 OR novolog[Title/Abstract] OR
 novorapid[Title/Abstract] OR
 humalog[Title/Abstract] OR
 apidra[Title/Abstract]) OR
 ((metformin*[Title/Abstract] OR
 "Metformin"[Mesh:NoExp]) AND
 (jardiance*[Title/Abstract] OR BI-
 10773[Title/Abstract] OR BI
 10773[Title/Abstract] OR
 BI10773[Title/Abstract] OR
 empagliflozin*[Title/Abstract] OR
 forxiga*[Title/Abstract] OR BMS-
 512148[Title/Abstract] OR BMS
 512148[Title/Abstract] OR
 BMS512148[Title/Abstract] OR
 dapagliflozin*[Title/Abstract] OR
 invokana*[Title/Abstract] OR
 canagliflozin*[Title/Abstract] OR
 "Canagliflozin"[Mesh] OR SGLT-2
 inhibitor*[Title/Abstract] OR SGLT 2
 inhibitor*[Title/Abstract] OR SGLT2

inhibitor*[Title/Abstract] OR
gliflozin*[Title/Abstract] OR sodium glucose
cotransporter 2 inhibitor*[Title/Abstract] OR
sodium glucose co transporter 2
inhibitor*[Title/Abstract] OR sodium glucose co-
transporter 2 inhibitor*[Title/Abstract] OR
sodium glucose transporter 2
inhibitor*[Title/Abstract] OR "Sodium-Glucose
Transporter 2 Inhibitors"[Mesh] OR
oltar*[Title/Abstract] OR
amarel*[Title/Abstract] OR
amaryl*[Title/Abstract] OR HOE-
490[Title/Abstract] OR HOE 490[Title/Abstract]
OR HOE490[Title/Abstract] OR
glymepiride*[Title/Abstract] OR
glimepiride*[Title/Abstract] OR
glibenese*[Title/Abstract] OR
glupitel*[Title/Abstract] OR
ozidia*[Title/Abstract] OR
melizide*[Title/Abstract] OR
mindiab*[Title/Abstract] OR
minidiab*[Title/Abstract] OR
glucotrol*[Title/Abstract] OR
glydiazinamide*[Title/Abstract] OR
glidiazinamid*[Title/Abstract] OR
glypidizine*[Title/Abstract] OR
minodiab*[Title/Abstract] OR K-
4024[Title/Abstract] OR K 4024[Title/Abstract]
OR K4024[Title/Abstract] OR
glipizide*[Title/Abstract] OR "Glipizide"[Mesh]
OR diaprel*[Title/Abstract] OR
diabrezide*[Title/Abstract] OR
diamicron*[Title/Abstract] OR
glyade*[Title/Abstract] OR
glyclazide*[Title/Abstract] OR S-
1702[Title/Abstract] OR S 1702[Title/Abstract]
OR S1702[Title/Abstract] OR S-
852[Title/Abstract] OR S 852[Title/Abstract] OR
S852[Title/Abstract] OR
gliclazide*[Title/Abstract] OR "Gliclazide"[Mesh]
OR sulphonylurea*[Title/Abstract] OR
sulfonylureas*[Title/Abstract] OR "Sulfonylurea
Compounds"[Mesh:NoExp] OR AD
4833[Title/Abstract] OR AD-4833[Title/Abstract]
OR AD4833[Title/Abstract] OR

actos*[Title/Abstract] OR
pioglitazone*[Title/Abstract] OR
TZD[Title/Abstract] OR
glitazone*[Title/Abstract] OR
thiazolidinedione*[Title/Abstract] OR
"Pioglitazone"[Mesh] OR
"Thiazolidinediones"[Mesh:NoExp] OR
vipidia*[Title/Abstract] OR
nesina*[Title/Abstract] OR SYR-
322[Title/Abstract] OR SYR322[Title/Abstract]
OR SYR 322[Title/Abstract] OR
alogliptin*[Title/Abstract] OR
galvus*[Title/Abstract] OR LAF-
237[Title/Abstract] OR LAF237[Title/Abstract]
OR LAF 237[Title/Abstract] OR
vildagliptin[Title/Abstract] OR
"Vildagliptin"[Mesh] OR
tradjenta*[Title/Abstract] OR
trajenta*[Title/Abstract] OR BI-
1356[Title/Abstract] OR BI 1356[Title/Abstract]
OR BI1356[Title/Abstract] OR
linagliptin*[Title/Abstract] OR
"Linagliptin"[Mesh] OR onglyza*[Title/Abstract]
OR BMS-477118[Title/Abstract] OR
BMS477118[Title/Abstract] OR BMS
477118[Title/Abstract] OR
saxagliptin*[Title/Abstract] OR
januvia*[Title/Abstract] OR MK-
0431[Title/Abstract] OR MK0431[Title/Abstract]
OR MK 0431[Title/Abstract] OR
sitagliptin*[Title/Abstract] OR "Sitagliptin
Phosphate"[Mesh:NoExp] OR
gliptin*[Title/Abstract] OR dpp IV
inhibitor*[Title/Abstract] OR dpp 4
inhibitor*[Title/Abstract] OR
dipeptidylpeptidase IV inhibitor*[Title/Abstract]
OR dipeptidylpeptidase 4
inhibitor*[Title/Abstract] OR dipeptidyl
peptidase IV inhibitor*[Title/Abstract] OR
dipeptidyl peptidase 4 inhibitor*[Title/Abstract]
OR "Dipeptidyl-Peptidase IV Inhibitors"[Mesh]
OR NN-9924[Title/Abstract] OR
NN9924[Title/Abstract] OR
NN9535[Title/Abstract] OR NN-
9535[Title/Abstract] OR

	<p>Semaglutide[Title/Abstract] OR AC 2993[Title/Abstract] OR Exendin 4[Title/Abstract] OR Peptide, Ex4[Title/Abstract] OR Ex4 Peptide[Title/Abstract] OR Exendin-4[Title/Abstract] OR AC 2993 LAR[Title/Abstract] OR ITCA 650[Title/Abstract] OR Bydureon[Title/Abstract] OR Exenatide[Title/Abstract] OR Trulicity[Title/Abstract] OR LY2189265[Title/Abstract] OR LY-2189265[Title/Abstract] OR LY2189265[Title/Abstract] OR Dulaglutide[Title/Abstract] OR AVE-0010[Title/Abstract] OR AVE0010[Title/Abstract] OR AVE 0010[Title/Abstract] OR AVE-010[Title/Abstract] OR AVE 010[Title/Abstract] OR Lyxumia[Title/Abstract] OR ZP-10[Title/Abstract] OR ZP 10[Title/Abstract] OR ZP10A peptide[Title/Abstract] OR AQVE-10010[Title/Abstract] OR Adlyxin[Title/Abstract] OR Lixisenatide[Title/Abstract] OR NN-2211[Title/Abstract] OR NN2211[Title/Abstract] OR NN 2211[Title/Abstract] OR Saxenda[Title/Abstract] OR Victoza[Title/Abstract] OR Liraglutide[Title/Abstract] OR "semaglutide" [Supplementary Concept] OR "Exenatide"[Mesh] OR "dulaglutide" [Supplementary Concept] OR "lixisenatide" [Supplementary Concept] OR "Liraglutide"[Mesh] OR "Glucagon-Like Peptide-1 Receptor"[Mesh] OR "Glucagon-Like Peptide 1"[Mesh]))) AND (intensive[Title/Abstract] OR intensification[Title/Abstract] OR add-on[Title/Abstract] OR add-ons[Title/Abstract] OR addition[Title/Abstract] OR uncontrolled OR inadequately controlled OR combined OR combination)) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])</p>
Tulemuste arv	470, ajalise filtriga 406

Andmebaasi filtrid	Lisafiltritega (language English ja species Humans) 347
Ajaline piirang (ilmumisaeg)	01.01.2009-13.11.2020
Muud piirangud	–

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Metaanalüüsid, mis põhinevad randomiseeritud kontrollitud uuringutel
- Inglise keeles
- Kaasavad II tüüpi diabeetikut vanemad kui 18. a.

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Muud tüüpi diabeet
- Uuringud, mis ei käsitle huvipakkuvaid tulemusnäitajaid
- Loomkatsed

Sirveotsinguga (*hand search*) leitud artiklid: –

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: (arv) 314

Täistekstide põhjal raportist välja jäetud allikad: (arv põhjuste kaupa)

- 1) Ei tea mitu ravimrühma ja mis preparaadid on taustaks – 1
- 2) Erinev taustteraapia - 2
- 3) Võrdlus platseeboga – 4
- 4) Võrdleb muutust algväärtusega – 5
- 5) Sama võrdlus (DPP-4 vs SU), vähem uuringuid, teised kattuvad – 4
- 6) Uuringutes võrreldi ravimeid eraldi, mitte ravimgruppe - 2

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus nr 8: *Kas kõigil südame-veresoonkonna haiguse riskiga või olemasoleva südame-veresoonkonna haigusega 2. tüüpi diabeeti põdevatel inimestel kasutada raviskeemis SGLT2 inhibiitorit võrreldes selle mittekasutamisega, parema kardiovaskulaarse ravitulemuse saamiseks?*

Kuupäev (pp.kk.aasta)	15.12.2020
Otsingu läbiviija	Pille Meinson
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	<p>((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND (jardiance*[Title/Abstract] OR BI-10773[Title/Abstract] OR BI 10773[Title/Abstract] OR BI10773[Title/Abstract] OR empagliflozin*[Title/Abstract] OR forxiga*[Title/Abstract] OR BMS-512148[Title/Abstract] OR BMS 512148[Title/Abstract] OR</p>

	<p>BMS512148[Title/Abstract] OR dapagliflozin*[Title/Abstract] OR invokana*[Title/Abstract] OR canagliflozin*[Title/Abstract] OR "Canagliflozin"[Mesh] OR SGLT-2 inhibitor*[Title/Abstract] OR SGLT 2 inhibitor*[Title/Abstract] OR SGLT2 inhibitor*[Title/Abstract] OR gliflozin*[Title/Abstract] OR sodium glucose cotransporter 2 inhibitor*[Title/Abstract] OR sodium glucose co transporter 2 inhibitor*[Title/Abstract] OR sodium glucose co- transporter 2 inhibitor*[Title/Abstract] OR sodium glucose transporter 2 inhibitor*[Title/Abstract] OR "Sodium-Glucose Transporter 2 Inhibitors"[Mesh] OR PF- 04971729[Title/Abstract] OR PF04971729[Title/Abstract] OR PF 04971729[Title/Abstract] OR Steglatro[Title/Abstract] OR "ertugliflozin" [Supplementary Concept])) AND ("Cardiovascular Diseases"[Mesh:NoExp] OR "Myocardial Infarction"[Mesh:NoExp] OR "Myocardial Ischemia"[Mesh:NoExp] OR "Ventricular Dysfunction"[Mesh:NoExp] OR cardiovascular[Title/Abstract] OR cardiac[Title/Abstract] OR myocardial[Title/Abstract] OR heart failure[Title/Abstract] OR "Heart Failure"[Mesh])) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])</p>
Tulemuste arv	Ilma piiranguteta: 172; ajalise piiranguga: 170; Koos filtritega (humans & english): 111
Andmebaasi filtrid	Liik (ingl species): inimesed Keel (ingl language): inglise keel
Ajaline piirang (ilmumisaeg)	01.01.2009–15.11.2020
Muud piirangud	-
Märkused	Esmane otsing teostati 15.11.2020. 24.11.2020 töörühma koosoleku eel selgus, et välja on

	<p>jäänud üks toimeaine: ertuglifloosin. 15.12.2020 korraldatud täiendatud otsingut (lisati ertuglifloosiini terminid) andmebaasis Pubmed (otsing piirati esialgse otsingu kuupäevaga 15.11.2020). Selle tulemusena lisandus kaks kirjet: Tsapas et al. (2020) ja Kumar et al. (2020). Lisaks täpsustus 24.11.2020 tööühma koosolekul et tööühm soovib näha ka rühmapõhiseid võrdluseid. Kõik kirjed vaadati selle eesmärgiga uuesti läbi.</p>
--	--

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- RCT ja RCT-del põhinevad süstemaatilised ülevaated
- Uuringud mis käsitlevad SGLT2 järgmisi toimeaineid: dapaglifloosin, kanaglifloosin, empaglifloosin, ertuglifloosin
- Inglise keelsed

Välja jäetakse neile kriteeriumitele vastavad allikad:

- jälgimisuuringud

Sirveotsinguga (*hand search*) leitud artiklid: 2

Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. *Ann Intern Med* 2020;173(4):278-286

McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. *JAMA Cardiol.* 2020 Oct 7:e204511.

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 79

Täistekstide põhjal raportist välja jäetud allikad: 31 (vt põhjused Exceli fail).

Süstemaatilisest otsingust kaasati üks:

Heyward J, Mansour O, Olson L, Singh S, Alexander GC. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. *PLoS One.* 2020 Jun 5;15(6):e0234065.

Sirveotsingust kaasati kaks:

Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. *Ann Intern Med* 2020;173(4):278-286

McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2020 Oct 7:e204511.

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus nr 8: *Kas kõigil südame-veresoonkonna haiguse riskiga või olemasoleva südame-veresoonkonna haigusega 2. tüüpi diabeeti põdevatel inimestel kasutada raviskeemis SGLT2 inhibiitorit võrreldes selle mittekasutamise, parema kardiovaskulaarse ravitulemuse saamiseks?*

Lisaotsing: KÕRVALTOIMED

Kuupäev (pp.kk.aasta)	18.12.2020
Otsingu läbiviija	Pille Meinson
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus,

Type 2"[Mesh]) AND (jardiance*[Title/Abstract] OR BI-10773[Title/Abstract] OR BI 10773[Title/Abstract] OR BI10773[Title/Abstract] OR empagliflozin*[Title/Abstract] OR forxiga*[Title/Abstract] OR BMS-512148[Title/Abstract] OR BMS 512148[Title/Abstract] OR BMS512148[Title/Abstract] OR dapagliflozin*[Title/Abstract] OR invokana*[Title/Abstract] OR canagliflozin*[Title/Abstract] OR "Canagliflozin"[Mesh] OR SGLT-2 inhibitor*[Title/Abstract] OR SGLT 2 inhibitor*[Title/Abstract] OR SGLT2 inhibitor*[Title/Abstract] OR gliflozin*[Title/Abstract] OR sodium glucose cotransporter 2 inhibitor*[Title/Abstract] OR sodium glucose co transporter 2 inhibitor*[Title/Abstract] OR sodium glucose co-transporter 2 inhibitor*[Title/Abstract] OR sodium glucose transporter 2 inhibitor*[Title/Abstract] OR "Sodium-Glucose Transporter 2 Inhibitors"[Mesh] OR PF-04971729[Title/Abstract] OR PF04971729[Title/Abstract] OR PF 04971729[Title/Abstract] OR Steglatro[Title/Abstract] OR "ertugliflozin" [Supplementary Concept])) AND (adverse effect[Title/Abstract] OR adverse event[Title/Abstract] OR adverse reaction[Title/Abstract] OR Patient safety[Title/Abstract] OR drug safety[Title/Abstract] OR complications[Title/Abstract] OR side effect[Title/Abstract] OR "Drug-Related Side Effects and Adverse Reactions"[Mesh] OR "Long Term Adverse Effects"[Mesh] OR "adverse effects" [Subheading])) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])

Tulemuste arv	Ilma piiranguteta: 129 Ajalise piiranguga: 125 Lisafiltritega (humans ja english): 114
Andmebaasi filtrid	Liik: humans Keel: english
Ajaline piirang (ilmumisaeg)	01.01.2014–18.12.2020
Muud piirangud	-
Märkused	24.11.2020 koosolekul täpsustatud tulemusnäitajad: genitaal ja uroinfektsioon, ketoatsidoos, hüpovoleemia Kaasati 6 MA-d

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Süstemaatilised ülevaated ja meta-analüüsid, mis kaasavad RCT-sid
- Süstemaatilised ülevaated ja meta-analüüsid, mis käsitlevad SGLT2 inhibiitoreid rühmapõhiselt
- SGLT2 inhibiitorid vs. platseebo
- Järgmised tulemusnäitajad genitaal ja uroinfektsioon, ketoatsidoos, hüpovoleemia

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Süstemaatilised ülevaated ja meta-analüüsid, mis kaasavad jälgimisuuringuid
- Uuringud, kus pole meile huvipakkuvaid tulemusnäitajaid
- Võrdlusrühm aktiivne kontroll

Sirveotsinguga (*hand search*) leitud artiklid: –

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 99

Täistekstide põhjal raportist välja jäetud allikad: 9 (vt Exceli fail)

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus 9: *Kas kõigil südame-veresoonkonna haiguse riskiga või olemasoleva südame-veresoonkonna haigusega 2. tüüpi diabeeti põdevatel inimestel kasutada raviskeemis GLP1 agonisti võrreldes selle mittekasutamise, parema kardiovaskulaarse ravitulemuse saamiseks?*

Kuupäev (pp.kk.aasta)	14.11.2020
Otsingu läbiviija	Keiu Paapsi
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	<p>((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND (NN-9924[Title/Abstract] OR NN9924[Title/Abstract] OR NN9535[Title/Abstract] OR NN-9535[Title/Abstract] OR Semaglutide[Title/Abstract] OR AC 2993[Title/Abstract] OR Exendin 4[Title/Abstract] OR Peptide, Ex4[Title/Abstract] OR Ex4 Peptide[Title/Abstract] OR Exendin-</p>

4[Title/Abstract] OR AC 2993 LAR[Title/Abstract]
 OR ITCA 650[Title/Abstract] OR
 Bydureon[Title/Abstract] OR
 Exenatide[Title/Abstract] OR
 Trulicity[Title/Abstract] OR
 LY2189265[Title/Abstract] OR LY-
 2189265[Title/Abstract] OR LY
 2189265[Title/Abstract] OR
 Dulaglutide[Title/Abstract] OR AVE-
 0010[Title/Abstract] OR
 AVE0010[Title/Abstract] OR AVE
 0010[Title/Abstract] OR AVE-010[Title/Abstract]
 OR AVE 010[Title/Abstract] OR
 Lyxumia[Title/Abstract] OR ZP-10[Title/Abstract]
 OR ZP 10[Title/Abstract] OR ZP10A
 peptide[Title/Abstract] OR AQVE-
 10010[Title/Abstract] OR Adlyxin[Title/Abstract]
 OR Lixisenatide[Title/Abstract] OR NN-
 2211[Title/Abstract] OR NN2211[Title/Abstract]
 OR NN 2211[Title/Abstract] OR
 Saxenda[Title/Abstract] OR
 Victoza[Title/Abstract] OR
 Liraglutide[Title/Abstract] OR "semaglutide"
 [Supplementary Concept] OR
 "Exenatide"[Mesh] OR "dulaglutide"
 [Supplementary Concept] OR "lixisenatide"
 [Supplementary Concept] OR
 "Liraglutide"[Mesh] OR "Glucagon-Like Peptide-
 1 Receptor"[Mesh] OR "Glucagon-Like Peptide
 1"[Mesh])) AND ("Cardiovascular
 Diseases"[Mesh:NoExp] OR "Myocardial
 Infarction"[Mesh:NoExp] OR "Myocardial
 Ischemia"[Mesh:NoExp] OR "Ventricular
 Dysfunction"[Mesh:NoExp] OR
 cardiovascular[Title/Abstract] OR
 cardiac[Title/Abstract] OR
 myocardial[Title/Abstract] OR heart
 failure[Title/Abstract] OR "Heart
 Failure"[Mesh])) AND ("Meta-Analysis"
 [Publication Type] OR "Meta-Analysis as
 Topic"[Mesh] OR meta analy*[Title/Abstract]
 OR metanaly*[Title/Abstract] OR
 metaanaly*[Title/Abstract] OR systematic[sb])

Tulemuste arv	112
Andmebaasi filtrid	-
Ajaline piirang (ilmumisaeg)	01.01.2009-14.11.2020
Muud piirangud	Inglise keel
Märkused	-

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Metaanalüüs
- Süstemaatiline ülevaade
- 2. tüüpi diabeet
- GLP1 rühma sisene võrdlus
- Täiskasvanud patsiendid koronaarriiski või -haigusega

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Võrdlus teiste ravimrühmadega
- Muu uuringukavand (nt RCT, observational jne)
- Muu sekkumisgrupp (nt gestatsiooni diabeet, lapsed, 1. tüüpi diabeedi patsiendid)
- Muu tulem (KMI, HbA1c)

Sirveotsinguga (*hand search*) leitud artikleid:

Esialgne otsing – 112

Lisatud ajapiirang (alates 2009) – 112

Lisatud keelepiirang (inglise) – 108

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 86

Täistekstide põhjal raportist välja jäetud allikad: (arv põhjuste kaupa)

2 – artikkel polnud täistekstina kättesaadav

1 – tulem liiga kaudne

1 – kontrollgrupid ühendatud (platseebo+muud ravimrühmad)

11 – juba kaasatud (MA-sse kaasatud RCT-d kattuvad uuematesse MA-desse kaasatud uuringutega)

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus 9: *Kas kõigil südame-veresoonkonna haiguse riskiga või olemasoleva südame-veresoonkonna haigusega 2. tüüpi diabeeti põdevatel inimestel kasutada raviskeemis GLP1 agonisti võrreldes selle mittekasutamise, parema kardiovaskulaarse ravitulemuse saamiseks?*

Lisaotsing: KÕRVALTOIMED

Kuupäev (pp.kk.aasta)	13.12.2020
Otsingu läbiviija	Keiu Paapsi
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND (NN-9924[Title/Abstract] OR NN9924[Title/Abstract] OR NN9535[Title/Abstract] OR NN-9535[Title/Abstract] OR Semaglutide[Title/Abstract] OR AC 2993[Title/Abstract] OR Exendin 4[Title/Abstract] OR Peptide, Ex4[Title/Abstract])

OR Ex4 Peptide[Title/Abstract] OR Exendin-4[Title/Abstract] OR AC 2993 LAR[Title/Abstract] OR ITCA 650[Title/Abstract] OR Bydureon[Title/Abstract] OR Exenatide[Title/Abstract] OR Trulicity[Title/Abstract] OR LY2189265[Title/Abstract] OR LY-2189265[Title/Abstract] OR LY2189265[Title/Abstract] OR Dulaglutide[Title/Abstract] OR AVE-0010[Title/Abstract] OR AVE0010[Title/Abstract] OR AVE0010[Title/Abstract] OR AVE-010[Title/Abstract] OR AVE 010[Title/Abstract] OR Lyxumia[Title/Abstract] OR ZP-10[Title/Abstract] OR ZP 10[Title/Abstract] OR ZP10A peptide[Title/Abstract] OR AQVE-10010[Title/Abstract] OR Adlyxin[Title/Abstract] OR Lixisenatide[Title/Abstract] OR NN-2211[Title/Abstract] OR NN2211[Title/Abstract] OR NN 2211[Title/Abstract] OR Saxenda[Title/Abstract] OR Victoza[Title/Abstract] OR Liraglutide[Title/Abstract] OR "semaglutide" [Supplementary Concept] OR "Exenatide"[Mesh] OR "dulaglutide" [Supplementary Concept] OR "lixisenatide" [Supplementary Concept] OR "Liraglutide"[Mesh] OR "Glucagon-Like Peptide-1 Receptor"[Mesh] OR "Glucagon-Like Peptide 1"[Mesh])) AND (adverse effect[Title/Abstract] OR adverse event[Title/Abstract] OR adverse reaction[Title/Abstract] OR Patient safety[Title/Abstract] OR drug safety[Title/Abstract] OR complications[Title/Abstract] OR side effect[Title/Abstract] OR "Drug-Related Side Effects and Adverse Reactions"[Mesh] OR "Long Term Adverse Effects"[Mesh] OR "adverse effects" [Subheading])) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])

Tulemuste arv	136
Andmebaasi filtrid	-
Ajaline piirang (ilmumisaeg)	01.01.2014-13.12.2020
Muud piirangud	-
Märkused	-

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Metaanalüüs, süstemaatiline ülevaade
- Tulem pankreatiit, pankrease vähk, seedetrakti kõrvaltoimed
- 2. tüüpi diabeet
- GLP1 rühma võrdlus platseebo või muu ravimiga
- Täiskasvanud patsiendid

Välja jäetakse neile kriteeriumitele vastavad allikad:

- GLP1 rühmasisene võrdlus
- Muu tulem (nt luumurrud)
- Muu sekkumisgrupp (lapsed)
- GLP1 analüüsitud koos muu ravimgrupiga (DPP4 inhibiitorid)

Sirveotsinguga (*hand search*) leitud artikleid:

Esialgne otsing – 136 vastet

Lisatud ajapiirang (alates 2014) – 106 vastet

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 92

Täistekstide põhjal raportist välja jäetud allikad: (arv põhjuste kaupa)

2 – GLP1 rühmasisene võrdlus

1 – GLP1 ja DPP4 analüüsitud koos

1 – üksikravim (GLP1) võrdlus platseeboga/ravimiga

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus 10: *Kas kõigil 2. tüüpi diabeeti põdevatel inimestel kasutada tavapäraseid või intensiivseid HbA1c eesmärkväärtuseid parema ravitulemuse saavutamiseks?*

Kuupäev (pp.kk.aasta)	12.09.2020
Otsingu läbiviija	Helena Lepassar
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	<p>((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND (((((((("Glycated Hemoglobin A"[Majr:NoExp]) OR (hemoglobin*[Title/Abstract] AND glyc*[Title/Abstract])) OR (haemoglobin*[Title/Abstract] AND glyc*[Title/Abstract])) OR (glycohemoglobin*[Title/Abstract])) OR</p>

	<pre>(glycohaemoglobin*[Title/Abstract])) OR (hba1c[Title/Abstract] OR hb a1C[Title/Abstract])) OR ((((("Fasting"[Majr:NoExp]) OR ("Postprandial Period"[Majr:NoExp])) OR (fast*[Title/Abstract])) OR (diet[Title/Abstract] AND restrict*[Title/Abstract])) OR (postprandial*[Title/Abstract] OR post- prandial*[Title/Abstract])) AND (("Blood Glucose"[Majr:NoExp]) OR ((blood*[Title/Abstract] OR plasma*[Title/Abstract] OR serum*[Title/Abstract]) AND (gluc*[Title/Abstract] OR sugar*[Title/Abstract]))) AND ((((Intensiv*[Title/Abstract] OR aggressiv*[Title/Abstract] OR rigorous*[Title/Abstract] OR tight*[Title/Abstract]) AND (glucose*[Title/Abstract] OR glycaemic*[Title/Abstract] OR glycemic*[Title/Abstract]) AND (control*[Title/Abstract] OR lower*[Title/Abstract])) OR ((Intensiv*[Title/Abstract] AND (strateg*[Title/Abstract] OR therap*[Title/Abstract] OR treat*[Title/Abstract] OR process*[Title/Abstract] OR protocol*[Title/Abstract]))) OR (TGC[Title/Abstract]))) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])</pre>
Tulemuste arv	124
Andmebaasi filtrid	–
Ajaline piirang (ilmumisaeg)	01.01.2009–
Muud piirangud	–

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Sihtrühm: 2. tüüpi diabeeti põdevad patsiendid
- Süstemaatilised ülevaated ja meta-analüüsid
- Inglisekeelsed uuringud

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Valimis ka 1. tüüpi diabeeti põdevad patsiendid
- Valimis gestatsioonidiabeeti põdevad patsiendid
- Uuringus ei käsitletud kliinilises küsimuses toodud tulemusnäitajaid
- Uuringud, mis käsitlevad ainult intensiivset versus standard insuliinravi

Sirveotsinguga (*hand search*) leitud artiklid: 1 (Hemmingsen B, Lund SS, Gluud C et al. (2011) Intensive glycaemic control for patients with type 2 diabetes: Systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. *BMJ (Online)*.343 (7834) (pp 1136), 2011.Article Number: d6898.Date of Publication: 03 Dec 2011. 1136)

Ravijuhendisse kaasatud allikad: 2

Hasan R, Firwana B, Elraiyah T, Domecq JP, Prutsky G, Nabhan M, Prokop LJ, Henke P, Tsapas A, Montori VM, Murad MH. A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. *J Vasc Surg*. 2016 Feb;63(2 Suppl):22S-28S.e1-2. doi: 10.1016/j.jvs.2015.10.005. PMID: 26804364.

Herrera-Gómez F, Asensio-González M, González-López A, Álvarez FJ. Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis. *Front Pharmacol*. 2017 Nov 21;8:845. doi: 10.3389/fphar.2017.00845. PMID: 29209216; PMCID: PMC5702491.

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 116

Täistekstide põhjal raportist välja jäetud allikad: 6

1. Macisaac RJ, Jerums G. Intensive glucose control and cardiovascular outcomes in type 2 diabetes. *Heart Lung Circ*. 2011;20(10):647-654. doi:10.1016/j.hlc.2010.07.013. Ülevaateartikkel varem teostatud meta-analüüsides ja jälgimisuuringutest
2. Ma J, Yang W, Fang N, Zhu W, Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. *Nutr Metab Cardiovasc Dis*. 2009;19(9):596-603. doi:10.1016/j.numecd.2009.07.004. Vana artikkel, uuemad sisaldavad samu tulemusnäitajaid, aga kaasatud rohkem RCT-id.

3. Zhang CY, Sun AJ, Zhang SN, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. *Ann Med*. 2010;42(4):305-315. doi:10.3109/07853891003796752. Vana artikkel, uemates samad tulemusnäitajad, rohkem RCT-id.
4. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet*. 2009;373(9677):1765-1772. doi:10.1016/S0140-6736(09)60697-8. Vana artikkel, uemates samad tulemusnäitajad, rohkem RCT-id.
5. Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. *Diab Vasc Dis Res*. 2010;7(2):119-130. doi:10.1177/1479164109353367. Vana artikkel, uemad käsitlevad samu RCT-sid, tulemusnäitajad samad.
6. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycaemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. *Nutr Metab Cardiovasc Dis*. 2009;19(9):604-612. doi:10.1016/j.numecd.2009.03.021. Vana artikkel, uemad käsitlevad samu tulemusnäitajaid, samad RCT-d.

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliinilised küsimused number 11 ja 12:

Kas kõik 2. tüüpi diabeeti põdevad patsiendid, kelle raviskeem ei sisalda insuliini, peaksid kontrollima vere glükoosisaldust glükomeetriga või mitte parema ravitulemuse saavutamiseks?

Kas kõik 2. tüüpi diabeeti põdevad patsiendid, kelle raviskeem sisaldab insuliini, peaksid kontrollima vere glükoosisaldust glükomeetriga või mitte?

Kuupäev (pp.kk.aasta)	17.09.2020
Otsingu läbiviija	Keiu Paapsi
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND (((((((("Blood Glucose Self-Monitoring"[Mesh]) OR ((Self-monitor*[Title] OR self monitor*[Title] OR home-monitor*[Title] OR home monitor*[Title]) AND (glucose*[Title] OR sugar*[Title] OR

	<p>blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (((Self-test*[Title] OR self test*[Title] OR home-test*[Title] OR home test*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (((Self-assess*[Title] OR self assess*[Title] OR home-assess*[Title] OR home assess*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (((Self-manag*[Title] OR self manage*[Title] OR home-manage*[Title] OR home manage*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (((Self-control*[Title] OR self control*[Title] OR home-control*[Title] OR home control*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (SMBG[Title])) OR (Fingerprick*[Title] OR fingerstick*[Title])) OR (((Finger*[Title] OR thumb*[Title]) AND (prick*[Title] OR stick*[Title]))) OR ((Blood[Title] AND glucose*[Title] AND meter*[Title]))) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])</p>
Tulemuste arv	89
Andmebaasi filtrid	-
Ajaline piirang (ilmumisaeg)	01.01.2014-17.09.2020
Muud piirangud	-
Märkused	-

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Metaanalüüs
- Süstemaatiline ülevaade
- 2. tüüpi diabeet

- Sekkumine – *Self-monitoring of blood glucose* (SMBG)
- Täiskasvanud patsiendid

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Muu sekkumine (nt *continuous glucose monitoring*, CGM)
- Muu uuringukavand (nt RCT, observational jne)
- Muu sekkumisgrupp (nt gestatsiooni diabeet, lapsed, 1. tüüpi diabeedi patsiendid)
- Muu tulem (nt ravisõostumus, tehnoloogilised vahendid)

Sirveotsinguga (*hand search*) leitud artikleid:

Esialgne otsing – 89 vastet

Lisatud ajapiirang (alates 2014) – 34 vastet

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 24

Täistekstide põhjal raportist välja jäetud allikad: (arv põhjuste kaupa)

2 – muu tulem (kaudne tõendus)

2 – metanalüüsi kaasatud artiklid kattuvad juba sisestatud uuringutega

2 – muu sekkumine (CGM)

1 – kasutuses olevaid erinevaid meetodikaid kirjeldav süstemaatiline ülevaade

1 – koos on käsitletud nii T1DM kui T2DM patsiente (kaudne tõendus)

Sisestada kaks:

Xu Y, Tan DHY, Lee JY. Evaluating the impact of self-monitoring of blood glucose frequencies on glucose control in patients with type 2 diabetes who do not use insulin: A systematic review and meta-analysis. *Int J Clin Pract.* 2019;73(7):e13357 (K11)

Zhu H, Zhu Y, Leung SW. Is self-monitoring of blood glucose effective in improving glycaemic control in type 2 diabetes without insulin treatment: a meta-analysis of randomised controlled trials. *BMJ Open.* 2016;6(9):e010524 (K11)

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliinilised küsimused number 11 ja 12:

Kas kõik 2. tüüpi diabeeti põdevad patsiendid, kelle raviskeem ei sisalda insuliini, peaksid kontrollima vere glükoosisaldust glükomeetriga või mitte parema ravitulemuse saavutamiseks?

Kas kõik 2. tüüpi diabeeti põdevad patsiendid, kelle raviskeem sisaldab insuliini, peaksid kontrollima vere glükoosisaldust glükomeetriga või mitte?

Kuupäev (pp.kk.aasta)	21.02.2020
Otsingu läbiviija	Keiu Paapsi
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND (((((((("Blood Glucose Self-Monitoring"[Mesh]) OR ((Self-monitor*[Title] OR self monitor*[Title] OR home-monitor*[Title] OR home monitor*[Title])

	<p>AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title])) OR (((Self-test*[Title] OR self test*[Title] OR home-test*[Title] OR home test*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title])))) OR (((Self-assess*[Title] OR self assess*[Title] OR home-assess*[Title] OR home assess*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title])))) OR (((Self-manag*[Title] OR self manage*[Title] OR home-manage*[Title] OR home manage*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title])))) OR (((Self-control*[Title] OR self control*[Title] OR home-control*[Title] OR home control*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title])))) OR (SMBG[Title]) OR (Fingerprick*[Title] OR fingerstick*[Title]) OR (((Finger*[Title] OR thumb*[Title]) AND (prick*[Title] OR stick*[Title])))) OR ((Blood[Title] AND glucose*[Title] AND meter*[Title])) AND ("randomized controlled trial"[Publication Type] OR "randomized controlled trials as topic"[MeSH Terms] OR "randomized controlled trial*"[Title/Abstract] OR "randomized control trial*"[Title/Abstract] OR ("clinical trial"[Publication Type] AND ("random allocation"[MeSH Terms] OR "random*"[Title/Abstract] OR "double-blind method"[MeSH Terms] OR "double blind*"[Title/Abstract]))))</p>
Tulemuste arv	481
Andmebaasi filtrid	-
Ajaline piirang (ilmumisaeg)	01.01.2014
Muud piirangud	-
Märkused	-

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Randomiseeritud kontrollitud uuring (RCT)
- 2. tüüpi diabeet
- Sekkumine – *Self-monitoring of blood glucose* (SMBG)
- Täiskasvanud patsiendid

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Muu sekkumine (nt *continuous glucose monitoring*, CGM)
- Muu uuringukavand (nt metaanalüüs, observational jne)
- Muu sekkumisgrupp (nt gestatsiooni diabeet, lapsed, 1. tüüpi diabeedi patsiendid)
- Muu tulem (nt ravisoostumus, tehnoloogilised vahendid)
- Muus keeles artikkel

Sirveotsinguga (*hand search*) leitud artikleid:

Esialgne otsing – 481 vastet

Ajaline piirang (2014) – 211 vastet

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 175

Täistekstide põhjal raportist välja jäetud allikad: (arv põhjuste kaupa)

17 – muu sekkumine

2 – muu tulem

6 – juba sisestatud

1 – muu vanusgrupp

4 – muu uuringukavand

1 – täistekst saksa keeles

Sisestada viis:

Nishimura A, Harashima SI, Fujita Y, Tanaka D, Wang Y, Liu Y, Inagaki N. Effects of structured testing versus routine testing of blood glucose in diabetes self-management: A randomized controlled trial. *J Diabetes Complications*. 2017 Jan;31(1):228-233 (K11)

Machry RV, Rados DV, Gregório GR, Rodrigues TC. Self-monitoring blood glucose improves glycemic control in type 2 diabetes without intensive treatment: A systematic review and meta-analysis. *Diabetes Res Clin Pract*. 2018 Aug;142:173-187 (K11)

Li CL, Wu YC, Kornelius E, Chen YJ, Lin YT, Hsiao HW, Peng CH, Yang YS, Huang CN. Comparison of Different Models of Structured Self-Monitoring of Blood Glucose in Type 2 Diabetes. *Diabetes Technol Ther.* 2016 Mar;18(3):171-7 (K11)

Gao L, Ji L, Su Q, Feng B, Shan Z, Hu R, Xing X, Xue Y. Impact of structured self-monitoring of blood glucose on the quality of life of insulin-treated Chinese patients with type 2 diabetes mellitus: Results from the COMPASS study. *Diabetes Res Clin Pract.* 2016 Feb;112:88-93 (K12)

Hortensius J, Kleefstra N, Landman GWD, Houweling BT, Groenier KH, van der Bijl JJ, Bilo H. Effects of three frequencies of self-monitored blood glucose on HbA1c and quality of life in patients with type 2 diabetes with once daily insulin and stable control: a randomized trial. *BMC Res Notes.* 2018 Jan 15;11(1):26 (K12)

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus number 12:

Kas kõik 2. tüüpi diabeeti põdevad patsiendid, kelle raviskeem sisaldab insuliini, peaksid kontrollima vere glükoosisaldust glükomeetriga või mitte?

Lisaotsing: AASTAARV LAIENDATUD

Kuupäev (pp.kk.aasta)	03.03.2021
Otsingu läbiviija	Keiu Paapsi
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin

	<p>dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND (((((((("Blood Glucose Self-Monitoring"[Mesh]) OR ((Self- monitor*[Title] OR self monitor*[Title] OR home-monitor*[Title] OR home monitor*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (((Self-test*[Title] OR self test*[Title] OR home-test*[Title] OR home test*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (((Self- assess*[Title] OR self assess*[Title] OR home- assess*[Title] OR home assess*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (((Self-manag*[Title] OR self manage*[Title] OR home-manage*[Title] OR home manage*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (((Self- control*[Title] OR self control*[Title] OR home- control*[Title] OR home control*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (SMBG[Title])) OR (Fingerprick*[Title] OR fingerstick*[Title])) OR (((Finger*[Title] OR thumb*[Title]) AND (prick*[Title] OR stick*[Title]))) OR ((Blood[Title] AND glucose*[Title] AND meter*[Title]))) AND ("Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analy*[Title/Abstract] OR metanaly*[Title/Abstract] OR metaanaly*[Title/Abstract] OR systematic[sb])</p>
Tulemuste arv	78
Andmebaasi filtrid	-

Ajaline piirang (ilmumisaeg)	01.01.2009 – 01.01.2014
Muud piirangud	Inglise keel, humans
Märkused	Kaasatud uuringud mis vastavad kliinilise küsimuse nr 12 kriteeriumitele. Kliinilise küsimuse nr 11 soovitude sõnastamiseks piisas eelnevast otsingust.

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Insuliini ravil olevad patsiendid
- 2. tüüpi diabeet
- Sekkumine – *Self-monitoring of blood glycose* (SMBG)
- Täiskasvanud patsiendid

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Muu sekkumine (nt *continuous glucose monitoring*, CGM)
- Muu sekkumisgrupp (nt gestatsiooni diabeet, lapsed, 1. tüüpi diabeedi patsiendid)
- Muu tulem (nt ravisõostumus, tehnoloogilised vahendid)
- Muus keeles artikkel

Sirveotsinguga (*hand search*) leitud artikleid:

Esialgne otsing – 78 vastet

Ajaline piirang (2009 – 2014) – 33 vastet

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 30

Täistekstide põhjal raportist välja jäetud allikad: (arv põhjuste kaupa)

3 – insuliini mitte tarvivad patsiendid

Otsingu protokoll:

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus number 12:

Kas kõik 2. tüüpi diabeeti põdevad patsiendid, kelle raviskeem sisaldab insuliini, peaksid kontrollima vere glükoosisisaldust glükomeetriga või mitte?

Lisaotsing: AASTAARV LAIENDATUD

Kuupäev (pp.kk.aasta)	03.03.2021
Otsingu läbiviija	Keiu Paapsi
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND (((((((("Blood Glucose Self-Monitoring"[Mesh]) OR ((Self-monitor*[Title] OR self monitor*[Title] OR home-monitor*[Title] OR home monitor*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR

	<p>advice*[Title]))) OR (((Self-test*[Title] OR self test*[Title] OR home-test*[Title] OR home test*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (((Self-assess*[Title] OR self assess*[Title] OR home-assess*[Title] OR home assess*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (((Self-manag*[Title] OR self manage*[Title] OR home-manage*[Title] OR home manage*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (((Self-control*[Title] OR self control*[Title] OR home-control*[Title] OR home control*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR glycaemi*[Title] OR advice*[Title]))) OR (SMBG[Title])) OR (Fingerprick*[Title] OR fingerstick*[Title])) OR (((Finger*[Title] OR thumb*[Title]) AND (prick*[Title] OR stick*[Title]))) OR ((Blood[Title] AND glucose*[Title] AND meter*[Title]))) AND ("randomized controlled trial"[Publication Type] OR "randomized controlled trials as topic"[MeSH Terms] OR "randomized controlled trial*"[Title/Abstract] OR "randomized control trial*"[Title/Abstract] OR ("clinical trial"[Publication Type] AND ("random allocation"[MeSH Terms] OR "random*"[Title/Abstract] OR "double-blind method"[MeSH Terms] OR "double blind*"[Title/Abstract])))</p>
Tulemuste arv	496
Andmebaasi filtrid	-
Ajaline piirang (ilmumisaeg)	01.01.2009 – 01.01.2014
Muud piirangud	Inglise keel, humans
Märkused	Kaasatud uuringud mis vastavad kliinilise küsimuse nr 12 kriteeriumitele. Kliinilise küsimuse nr 11 soovitude sõnastamiseks piisas eelnevast otsingust.

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Insuliini ravil olevad patsiendid
- 2. tüüpi diabeet
- Sekkumine – *Self-monitoring of blood glycose* (SMBG)
- Täiskasvanud patsiendid

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Muu sekkumine (nt *continuous glycose monitoring*, CGM)
- Muu sekkumisgrupp (nt gestatsiooni diabeet, lapsed, 1. tüüpi diabeedi patsiendid)
- Muu tulem (nt ravisoostumus, tehnoloogilised vahendid)
- Muus keeles artikkel

Sirveotsinguga (*hand search*) leitud artikleid:

Esialgne otsing – 496 vastet

Ajaline piirang (2009 – 2014) – 165 vastet

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 152

Täistekstide põhjal raportist välja jäetud allikad: 13 (arv põhjuste kaupa)

3 – insuliini mitte tarbivad patsiendid

3 – insuliini tarbivad ja mitte tarbivad analüüsitud koos

1 – T1DM ja T2DM analüüsitud koos

2 – muu võrdlusgrupp

1 – muu sekkumine

1 – diabeet ja teised kroonilised haigused

2 – muu tulem

Otsinguprotokoll: ravijuhend „2.tüüpi diabeedi diagnostika ja ravi“

Kliiniline küsimus number 12:

Kas kõik 2. tüüpi diabeeti põdevad patsiendid, kelle raviskeem sisaldab insuliini, peaksid kontrollima vere glükoosisaldust glükomeetriga või mitte?

Lisaotsing: jälgimisuuringud

Kuupäev (pp.kk.aasta)	27.02.2021
Otsingu läbiviija	Keiu Paapsi
Andmebaas (koos vahendaja nimega Nt MEDLINE (Ovid))	Pubmed
Otsistrateegia (päring)	<pre>((adult-onset diabetes mellitus[Title/Abstract] OR adult onset diabetes mellitus[Title/Abstract] OR maturity-onset diabetes mellitus[Title/Abstract] OR maturity onset diabetes mellitus[Title/Abstract] OR slow-onset diabetes mellitus[Title/Abstract] OR slow onset diabetes mellitus[Title/Abstract] OR NIDDM[Title/Abstract] OR T2D[Title/Abstract] OR stable diabetes mellitus[Title/Abstract] OR non-insulin-dependent diabetes mellitus[Title/Abstract] OR non-insulin dependent diabetes mellitus[Title/Abstract] OR non insulin dependent diabetes mellitus[Title/Abstract] OR ketosis-resistant diabetes mellitus[Title/Abstract] OR ketosis resistant diabetes mellitus[Title/Abstract] OR noninsulin-dependent diabetes mellitus[Title/Abstract] OR noninsulin dependent diabetes mellitus[Title/Abstract] OR type two diabetic*[Title/Abstract] OR type II diabetic*[Title/Abstract] OR type 2 diabetic*[Title/Abstract] OR type two diabete*[Title/Abstract] OR type II diabete*[Title/Abstract] OR type 2 diabete*[Title/Abstract] OR "Diabetes Mellitus, Type 2"[Mesh]) AND (((((((("Blood Glucose Self-Monitoring"[Mesh]) OR ((Self-monitor*[Title] OR self monitor*[Title] OR home-monitor*[Title] OR home monitor*[Title]) AND (glucose*[Title] OR sugar*[Title] OR blood*[Title] OR urine*[Title] OR</pre>

glycaemi*[Title] OR advice*[Title]))) OR (((Self-
 test*[Title] OR self test*[Title] OR home-
 test*[Title] OR home test*[Title]) AND
 (glucose*[Title] OR sugar*[Title] OR
 blood*[Title] OR urine*[Title] OR
 glycaemi*[Title] OR advice*[Title]))) OR (((Self-
 assess*[Title] OR self assess*[Title] OR home-
 assess*[Title] OR home assess*[Title]) AND
 (glucose*[Title] OR sugar*[Title] OR
 blood*[Title] OR urine*[Title] OR
 glycaemi*[Title] OR advice*[Title]))) OR (((Self-
 manag*[Title] OR self manage*[Title] OR home-
 manage*[Title] OR home manage*[Title]) AND
 (glucose*[Title] OR sugar*[Title] OR
 blood*[Title] OR urine*[Title] OR
 glycaemi*[Title] OR advice*[Title]))) OR (((Self-
 control*[Title] OR self control*[Title] OR home-
 control*[Title] OR home control*[Title]) AND
 (glucose*[Title] OR sugar*[Title] OR
 blood*[Title] OR urine*[Title] OR
 glycaemi*[Title] OR advice*[Title]))) OR
 (SMBG[Title])) OR (Fingerprick*[Title] OR
 fingerstick*[Title])) OR (((Finger*[Title] OR
 thumb*[Title]) AND (prick*[Title] OR
 stick*[Title]))) OR ((Blood[Title] AND
 glucose*[Title] AND meter*[Title]))) NOT
 (continuous glucose monitoring OR flash
 glucose monitoring OR sensor glucose
 monitoring) AND (Epidemiologic
 Studies[Mesh:NoExp] OR Case-Control
 Studies[Mesh] OR Cohort Studies[Mesh] OR
 Cross-Sectional Studies[Mesh:NoExp] OR
 (epidemiologic[Title/Abstract] AND
 (study[Title/Abstract] OR
 studies[Title/Abstract])) OR case
 control[Title/Abstract] OR
 (cohort[Title/Abstract] AND
 (study[Title/Abstract] OR
 studies[Title/Abstract])) OR cross
 sectional[Title/Abstract] OR cohort
 analy*[Title/Abstract] OR (follow
 up[Title/Abstract] AND (study[Title/Abstract] OR
 studies[Title/Abstract])) OR
 longitudinal[Title/Abstract] OR
 retrospective*[Title/Abstract] OR

	prospective*[Title/Abstract] OR (observ*[Title/Abstract] AND (study[Title/Abstract] or studies[Title/Abstract])) OR adverse effect*[Title/Abstract])
Tulemuste arv	584
Andmebaasi filtrid	-
Ajaline piirang (ilmumisaeg)	01.01.2009
Muud piirangud	Inglise keel, humans
Märkused	Sisestatud kliinilise küsimuse nr 12 alla: Lalic et al. (2016), Gao et al. (2016), Ji et al. (2017), Gonzalez et al. (2015)

Ravijuhendisse kaasatakse neile kriteeriumitele vastavad allikad:

- Insuliini ravil olevad patsiendid
- 2. tüüpi diabeet
- Sekkumine – *Self-monitoring of blood glucose* (SMBG)
- Täiskasvanud patsiendid

Välja jäetakse neile kriteeriumitele vastavad allikad:

- Muu sekkumine (nt *continuous glucose monitoring*, CGM)
- Muu sekkumisgrupp (nt gestatsiooni diabeet, lapsed, 1. tüüpi diabeedi patsiendid)
- Muu tulem (nt ravisõostumus, tehnoloogilised vahendid)
- Muus keeles artikkel

Sirveotsinguga (*hand search*) leitud artikleid:

Esialgne otsing – 584 vastet

Ajaline piirang (2009) – 389 vastet

Välja jäetud allikaid peale pealkirja/sisukokkuvõttega tutvumist: 368

Täistekstide põhjal raportist välja jäetud allikad: (arv põhjuste kaupa)

1 – insuliini tarvitamise staatus teadmata

1 – insuliini mitte tarvitavad patsiendid

3 – väikene osa valimist insuliinravil/analüüsitud koos sõltumata raviskeemist

4 – muu sekkumine

4 – muu tulem

2 – T1DM ja T2DM analüüsitud koos

2 – juba kaasatud uuring